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ABSTRACT
GENETIC EVALUATION OF CYTOCHROME-P450 EXPRESSION IN VARIOUS
REGIONS OF HUMAN UTERUS IN SMOKERS AND NONSMOKERS.
Satya Vijayanand Vadlamuri

1.Regiospecific expression of CYP1A1 and CYP1B1 in human uterus of nonsmokers:
CYP1A1 and CYP1B1, isoforms of Cytochrome P450 enzyme, are of significant
toxicological importance due to their role in catalytic activation of several procarcinogens. The goal
of this study was to investigate the expression of these isoforms in different regions of the human
uterus. Expression was determined in the endometrium, endocervix and squamous (exocervix)
regions from six nonsmoking women by using RT-PCR. The transcripts encoding for CYP1A1
were significantly higher (p<0.05) in the squamous (exocervix) region compared to other areas.
However the expression of CYP1B1 was significantly higher (p<0.05) in the endometrium.
CYP1B1 expression appeared to be extremely low in a woman in the secretory stage of the
menstural phase, relative to the endometrium of the other patients who were all in the proliferative
stage at hysterectomy. CYP1B1 mRNA was expressed in only 2/6 patients in the squamous
(exocervix) region and 3/5 patients in the cervix. CYP1A1 was also uniformly expressed in the
endometrium of all except one patient, in whom expression was minimal in the other regions. It
appears that variability in the expression of these isoforms may be responsible for the differential
susceptibility to cancer in women.
2. Influence of menstrual phase and smoking status on expression of CYP1A1 and CYP1B1 in
different regions of the uterus:
CYP1A1 and CYP1B1 isoforms exhibit significant role in the catalytic activation of
procarcinogens during metabolism of PAH compounds and in estrogen metabolism. The goal of
this study was to investigate the expression of these isoforms in different regions of the uterus
from smokers and nonsmokers. Uterine tissue was obtained from women (n=22) undergoing
hysterectomy. Sections of endometrium (ENDO), endocervix (CERV) and squamous region
(SR) were isolated, stored at -700C and expression was determined by RT PCR and relative
mRNA levels were measured with respect to β-actin. A 12-fold increase in CYP1A1 expression
was apparent in the CERV from smokers compared to nonsmokers. In the ENDO and SR a much
smaller induction of <2-fold was observed. No differences for CYP1A1 mRNA were explicit in
the 3 regions when comparing the proliferative and secretory phases of the menstrual cycle. A
significantly higher (p<0.005) expression of CYP1B1 (~20-fold) was observed in ENDO from
patients in the proliferative phase compared to secretory phase. CYP1B1 expression appeared to
be lower in smokers (by ~3-fold) in the ENDO and no measurable expression was observed in
the SR. These results indicate that CYP1A1 and CYP1B1 are expressed variably in different
regions of the human uterus. The expression of CYP1B1 may be susceptible both to hormonal
control and cigarette smoking. The variability in the expression of these isoforms may be
responsible for the differential susceptibility to cancer in some women.
3. The effect of menstrual phase on CYP3A expression in human endometrium:
The CYP3A family consists of four closely related proteins. Of these, CYP3A3/4 is the
most abundant P450 isoform and is responsible for metabolizing estrogen as well as a variety of

therapeutic agents, whereas CYP3A7, the fetal liver form, is involved in the biosynthesis of estriol.
The goal of this study was to evaluate the expression of these two major CYP3A isoforms in human
uterine tissue during the proliferative (PROL) and secretory (SEC) phases of the menstrual cycle.
Human endometrial tissue was collected from women undergoing hysterectomy (n=34), and frozen
at -700C. Total mRNA was extracted, quantified and RT PCR was carried out by using consensus
primers to express CYP3A. The PCR product of 453bp was transferred to nylon membrane and
was hybridized with specific internal oligo probes for CYP3A/4 or CYP3A7 labeled with 32P γATP. The relative intensity of hybridization for individual samples was determined after
autoradiography and using image quant software. Expression of CYP3A7 was significantly
increased (17-fold) in the PROL compared to SEC phase, whereas no differences were observed
(p>0.05) for CYP3A3/4. No significant differences were observed for either of the CYP3A
isoforms in overall comparison regardless of phase. However, CYP3A3/4 expression was
significantly decreased (30-fold) in smokers compared to nonsmokers (p<0.05) in SEC phase.
Furthermore, a 40-fold and a 20-fold higher expression of CYP3A7 and CYP3A3/4, respectively
were observed in the PROL relative to the SEC phase in smokers. Differential expression of
CYP3A isoforms in the menstrual phase between smokers and nonsmokers could determine the
toxicological role of these enzymes in women. Expression of CYP3A7 in endometrium appeared to
be several fold higher (~10-fold) in the proliferative phase compared to the secretory phase.
CYP3A4 expression was comparable between the two phases of the menstrual cycle. Relatively
minimal expression of both enzymes was observed in the cervix. The RTPCR results indicated
differential expression of CYP3A7 in various phases of the menstrual cycle. These results indicate
that CYP3A isoforms may be subject to hormonal regulation during the menstrual cycle in
endometrium of premenopausal women.
Key words: CYP1A1, CYP1B1, CYP3A3/3A4, CYP3A7, Human Uterus, Endometrial cancer,
Cervical cancer.
Supported by NCI grant # CA-62369
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CHAPTER

1

INTRODUCTION

INTRODUCTION
In the United States, uterine cancer is still one of the most predominant and prevalent
cancers among women. About 50,000 cases of uterine cancer were diagnosed in 1998 of which
36,100 were endometrial cancers and 13,700 were cervical cancers. World-wide about 400,000
cases of cervical cancer and 500,000 cases of endometrial cancer were estimated (American
Cancer Society, 1998).

Panel A

Panel B

Figure: 1. UTERUS: Uterine organ in Panel A and Cross Section of uterus in Panel B.
Figure 1 shows the structure of human uterus. Uterine cervix and endometrium are about
10 cm apart the same organ, which show different degrees of susceptibility to cancer. Among
2

smokers, the risk of cervical cancer increased by 3 -fold (p<0.05) whereas the risk of endometrial
cancer decreased by almost 50% (relative odds ratio 0.57)(Brisson et al. 1994; Austin et al.
1993). Therefore, with increased cigarette consumption there is a significant increase in the risk
of cervical cancer and statistically significant decrease in risk of endometrial cancer (Baron et al.
1986).
The risk factors for cervical cancer are human papilloma virus, older age, multiple sexual
partners, etc., whereas for endometrial cancer the risk factors are obesity, estrogen use, clinical
conditions causing hyper estrogenism, anovulation, nulliparity, etc. (Yager et al. 1996).
Polycyclic hydrocarbons (PAHs) such as Benzo (a) Pyrene (BP) and nitrosamines are
considered to be promutagenic. Cigarettes contain 10-50mg of BP per cigarette, smoked foods
have 100mg BP per kg, and environmental pollutants have PAHs as major components. Several
of the most common cancers occur in hormonally responsive tissues, including breast,
endometrium and ovary in women and prostate in men (Yager et al. 1996). The uterus,
especially, endometrium, undergoes profound cell multiplication and cell differentiation at
regular intervals, which are influenced by hormonal effects.
Cytochrome P450s (CYPs) are hemeproteins, which are induced in human tissues to
metabolize various xenobiotics, hormones and other substrates. CYPs oxidize the substrates
through a process of oxidation and electron transport from NADPH. Some of these CYPs
activate chemical carcinogens to their electrophilic forms, which can bind to DNA covalently
and cause mutations that trigger carcinogenesis. A principal goal of this research was to
investigate this mechanism, which may explain these observations.

3

It is well established that cigarette smoke is one of the main causes of lung cancer. The
convincing reason is the presence of benzo (a) pyrene like procarcinogens present in cigarette
smoke are reactivated by phase I metabolizing enzymes of Cytochrome P450 s and usually
detoxified by epoxide hydrolase/ glutathione - S- transferase. The BP is metabolically activated
to BP-7, 8 diol- 9, 10-epoxide (BPDE) which is highly reactive and forms covalent adducts with
cellular DNA which may result in mutations and/ or malignant transformation. Similar
mechanism of bulky DNA adduct formation could be responsible in explaining possible
endometrial and cervical cancers. Cytochromes exhibit an active oxidizing role in estrogen
metabolism. Smoking induces these CYPs and localized expressions of these CYPs in the uterine
tissue could exhibit variability in inactivation, which is possible through differential degrees of
inducement due to smoking or non-smoking.
I.

CYP1A1 AND CYP1B1 IN UTERINE TISSUE:
Considering uterine sensitivity to estrogenic stimulus, it is valid to assume that any

changes in the localized metabolism of the estrogens may significantly affect both the
physiologic and toxicological outcome. It has been shown that enhanced metabolism of
endogenous estrogens to catechols by Tetrachlorodibenzo-p-dioxin (TCDD) induced enzymes
may lead to increased oxidative DNA damage and hence contribute to TCDD-mediated
hepatocarcinogenicity in female rats (Tritscher et al. 1996). TCDD and other related carcinogens
exert their effect by interacting with the Ah-receptors, which induce the expression of the
cytochrome P450 family 1 genes - CYP1A1 and CYP1A2 (Walker et al.1995), as well as a
recently characterized new member of the family, CYP1B1 (Sutter et al. 1994; Tritscher et
al.1996).
4

Recent evidence suggests that CYP1B1 may be the primary E2 -4-hydroxylase (Hayes et
al. 1996). Although the 4-hydroxylation is a minor metabolic pathway and represents a
relatively small fraction of the total urinary catechol-estrogen content (Fishman 1976), it has
tissue specific importance. For example, the 4-hydroxylation of E2 is significant in the metabolic
control of estrogen homeostasis and in the human uterus the rate of E2 -4-hydroxylation
approaches or exceeds that of 2-hydroxylation (Liehr et al. 1995). Therefore, it is likely that
localized inactivation of the estrogens in the uterus is an important determinant in the
physiological as well as toxicological outcomes. To date, only one report (Hakkola et al. 1997)
exists in literature regarding the presence of these isoforms in one region within the uterus, but
no information exists regarding the expression of both isoforms in all regions within the human
uterus.
II.

CYP1A1 and CYP1B1 IN SMOKERS AND NONSMOKERS:
CYP1A1 is the key activating enzyme, which carries out both oxidation steps required to

form the most carcinogenic metabolite of BP, (+) benzo (a) pyrene-7, 8-diol-9, 10-epoxide
(BPDE). This diol-epoxide can form DNA adducts which may lead to mutations and eventually
trigger a cascade of events leading to malignant transformations (Nesnow et al. 1995).
Furthermore since the higher levels of CYP1A1 are induced in smokers (Conney 1982), the
likelihood of exposure to reactive metabolites is increased even further. Likewise, the reported
genetic polymorphism for CYP1A1 (Rannug et al. 1995; Nebert et al. 1996) may result in
variations in the activation of chemical carcinogens explaining differences in individual
susceptibility (Ikawa et al. 1995; Kaderlik et al. 1995). It is possible that the higher incidence of

5

cervical cancer in smokers and some endometrial cancer cases may be a result of exposure to BP
or other PAHs from cigarette smoke.
Unopposed estrogens are considered as a major risk factor in the etiology of endometrial
cancer (Key et al. 1988; Miller et al. 1990). Isoforms of the CYP1 family play a major role in
generating catechol estrogens (Dannan et al. 1986; Spink et al. 1994), e.g. human CYP1A1,
which is involved in the activation of BP and also metabolizes estrogens (Eugster et al. 1993).
Recently, CYP1B1 (Spink et al. 1992) has been reported to be linked to 4-hydroxylation (Hayes
et al. 1996) of estradiol.
III.

CYP3A3/3A4 AND CYP3A7 IN UTERUS:
The CYP3A subfamily of enzymes has been established as the most abundant CYP

subfamily in humans, representing about 30% of all hepatic CYPs (Slaughter et al. 1995). So far
four major isoforms have been identified in humans. They are CYP3A3, CYP3A4, CYP3A5 and
CYP3A7, of which CYP3A4 is the predominant hepatic isoform having 98% homology with
CYP3A3. CYP3A7 is a human fetal liver form, first isolated as a 16-α-dehydroepiandrosteronesulfate hydroxylase (Kitada et al. 1987). While several CYP450 isoforms have been implicated
in estrogen biotransformation, CYP3A4 is probably the major isoform (Aoyama et al. 1990;
Brian et al. 1990). CYP3A7 has been found to catalyze 16-α-hydroxylation of DHEA sulfate
(Kitada et al. 1987). It is believed that DHEA-s is a precursor to estrogen biosynthesis and also
in high concentrations, DHEA-s inhibits cell proliferation (Herrington et al.1990), interferes with
cellular respiration (Mohan et al. 1989), promotes cervical ripening (Sakyo et al. 1987) and
inhibits placental progesterone biosynthesis (Powell et al. 1986). Therefore CYP3A7 might be
indirectly involved in several physiologically relevant processes in the uterus.
6

Menses is generally regarded as ischemic necrosis of a functional layer caused by
contraction of spiral arteries dependent on sex hormone concentrations. The endometrium
undergoes its cycle of proliferation, differentiation and desquamation, based on levels of either
estrogen alone or of both estrogen and progesterone. Since the endometrium undergoes a
constant dynamic growth phase, and cyclic variability of other enzyme expressions has been
noted in literature (Otsuki et al. 1994), it is possible that CYP450 might also undergo similar
cyclic variability. The goal of this research was to evaluate the expression of the glucocorticoid
inducible (Schultz et al. 1993) CYP3A isoforms in the endometrium and cervix to investigate
whether these isoforms undergo cyclic expression during different phases of the menstrual cycle.
IV.

CYP3A3/3A4 AND 3A7 IN NONSMOKERS AND SMOKERS:
There are no references on smoking related activation of CYP3A. Substrate specificity of

CYP3A individual isozymes has not been fully elucidated. CYP3A was thought to be important in
modulating in vivo antitumor activity and levels of host toxicity. A study in rats and hamsters has
shown that there is no significant change in CYP3A isoforms in liver (Koide et al 1999). However
in another study preferential induction of CYP3A was noticed by DDT in a sex-related manner,
which suggested that CYP regulation could play an important role in endocrine disruption (SierraSantoyo et al. 2000). This evidence suggests a possible role for CYP3A in smokers.
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CHAPTER

2

LITERATURE REVIEW

LITERATURE REVIEW

BACKGROUND:

In 1958 Martin Klingenberg reported the first evidence of P450 as a

subcellular fraction of rodent liver, and thereafter during last 40 years there has been an
explosive growth of investigations on Cytochrome P450 (CYP) (Costas 1996). Earlier studies
with human adult and fetal liver as well as human placenta (Kapitulnik et al. 1977a; Kapitulnik
et al. 1977b; Peldonen 1975) provided indirect evidence about the presence of multiple forms of
CYPs. Nebert (1987, 1989) claimed that, the P450- mediated monooxygenase system in
mammals can be compared to the immune system, due to the fact that a seemingly endless array
of chemical specificities for CYPs are possible. The techniques of molecular biology for cloning,
and determining the nucleotide sequence of P450 proteins and genes (Fujii-kuriyama et al. 1982;
Kawajiri et.al. 1984; Sogowa et al. 1985) provide the means to reveal the presence of multiple
forms which couldn't be determined by conventional biochemical methods.
UTERUS:

As shown in Figure 1 the body of the uterus is 1cm to 1.5 cm thick which is the

muscular portion called the myometrium. This myometrium is covered by a thin layer of mucous
membrane called the endometrium. Endometrial tissue consists of two types of cells - glandular
cells and stromal cells. A narrow neck is opened to the upper end of the vagina, which is called
cervix and this is richly covered with squamous epithelium. Cervix has many cellular types. At
the junction of cervix and endometrium is a squamous columnar junction (endocervix), which is
typically made up of a combination or continuous transformation of columnar cells and
squamous cells. Endometrium is always in a dynamic state of cyclic changes and is subjected to
various levels of estrogen and progestrone influence on the development, and differentiation of
the tissue during menstrual phase. The endometrium is a rapidly proliferating tissue, which is
9

always in an active state of mitotic changes under the influence of various hormones, cytokines,
enzymes and various genes. During this process, DNA adducts, if present, could be activating
oncogenes or inactivating tumor suppressor genes that lead to neoplastic transformations. There
is no published evidence on this to date, although speculations are made by many.
CARCINOGENESIS in UTERUS:

Exposure to diethyl stilbestrol (DES) has resulted in

cervico vaginal clear cell carcinoma in women and testicular cancer in men (Henderson et al.
1988; Berne, 1992) while prolonged use of anabolic steroids and oral contraceptives is associated
with increased risk for developing hepatocellular adenomas and carcinomas. The most widely
acknowledged effect of estrogens is increased cell proliferation (Nandi et al. 1995; Ethier, 1995).
Recently, it was reported that catechol estrogens can generate metabolites that can directly or
indirectly, through redox cycling process, generate reactive radical species causing oxidative
DNA damage (Liehr, 1994; Liehr and Roy 1990; Li et al. 1994). Breast cancer has been linked to
various environmental xenobiotics or their metabolites, some with estrogenic or androgenic
agonist and antagonist activities (Falck et al. 1992; el-Bayoumy 1992; Kelce et al. 1995;
MacMahon, 1994; Safe, 1995).
Smoking is known to be causative for many different types of cancers- mouth, pharynx,
larynx, oesophagus, lung, pancreas, kidney, bladder, pelvis and uterus (Schwab et al. 1997).
Cancer of the urinary bladder is a distant cancer where smoking is also considered to be a
causative factor (Hoffman et al. 1976; Molgavkar 1981). The relationship between smoking
related cancers like oral, lung, bladder, and cervical cancer has been postulated (Newell et al.
1974; Bailar 1963). An excess of urinary bladder tumors was seen among patients with cervical
cancer (Bailair 1963). There is 5-to 6 -fold higher risk of developing subsequent cases of oral
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and pharyngeal tumors among patients with cervical cancer (Newell et al. 1975). Further
evidence from Storm and Ewertz (1985) supported that risk of cancers of the lung, oesophagus,
bladder, and kidney occurred significantly above expectations in patients who suffered cervical
cancer. Among smokers, cigarette smoking appears to be a major risk factor in cervical intra
epithelial neoplasia (CIN) and invasive cervical cancer (Hellberg 1986; Nischan et al. 1988).
Habitual smoking and number of pregnancies increased the risk of cervical cancer (Hirose et al.
1996). A statistically significant dose-response relationship between cigarette smoking and
mortality rate due to uterine cancer was established (Akiba et al. 1990). No rationale has been
provided for explaining the relationship between smoking and cervical cancer. There is
overwhelming epidemiological evidence linking both of them. In spite of the reported evidence
suggesting that the metabolic pathway involving CYP and BP inactivation are implicated in
etiology of squamous cell carcinoma of the lung and the relationship of smoking to altered
incidence of various malignancies in uterine tissues, an exhaustive online and manual search of
biomedical literature for the past 50 years has shown only eleven original research articles
reporting CYP450 activity in human or animal uterine tissue. The previous literature until 1985
revolved around characterization of BP metabolism and DNA adduct formation (Dorman et al.
1981; Mass et al. 1981). It was reported that BP metabolites bind to DNA in endometrial tissue
cultures (Kaufman et al. 1980; Wilbanks et al. 1980; Dorman et al. 1981; Mass et al. 1981).
The role of BP is linked with lung cancer. The schematic representation of carcinogenic
effect from cigarette smoke is given in following Figure 2.1, as summarized by Mohamadi A
Sarkar in 1992 in the grant “Role of P450 & Detoxification Enzymes in Uterine Cancer”.
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Figure: 2.1 Sequence of events leading to carcinogenic effects from cigarette smoke
(MASarkar, 1992)
Carcinogenesis and cellular transformation is a multistep process, starting with initial
DNA lesions progressing through impairment and finally loss of normal cellular growth control
and gain of invasive and metastatic properties. A number of specific p53 mutations have been
identified in many human cancers. The molecular spectrum of p53 mutations has been
documented well especially in hepatic cancers, skin and lung cancers. Cigarette smoking is a
major risk factor for the incidence of lung cancer. Benzopyrene in cigarette smoke, causes p53
hot spot mutations at codons 157, 248 and 273 in lung cancer. A dose responsive increase of G to
T transversion mutations in p53 has been reported in lung cancer (Takeshima et al. 1993).
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Cigarette smoke contains many procarcinogens like (BP), which is a widely studied compound.
BP present in cigarette smoke is activated by CYP p450 enzymes such as CYP1A1 to form
epoxides which are potentially toxic. These are converted to comparatively less toxic substances
such as trans-dihydro diols by enzymes like epoxide hydrolase (EH). Subsequent oxidation
results in formation of diol-epoxides, which are toxic. (+) anti – BP-7,8 diol 9,10-epoxide
(BPDE) exhibits remarkable potency as a carcinogen on mouse skin and lungs of newborn mice.
DNA-BPDE adducts modify normal DNA structure and function (Peldonen et al. 1980). These
adducts also have carcinogenic potency in many animal and in vitro systems (Brookes et al.
1964; Goshman et.al. 1967; Shen et al. 1980; Nakayama et al.1984). BPDE- DNA adducts have
also been found in the squamous cells of invasive cervical carcinoma patients (Shamsuddin
et.al.1988). Although the correlation between CYP1A1 and BP metabolism was well
established, carcinogenicity depends on various other related mechanisms like DNA repair
mechanisms, alternative detoxifying mechanisms and individual susceptibility, etc. Therefore, it
is possible that individual variation in the activity of CYP enzymes could activate the
procarcinogens in cigarette smoke and make some of the smoking patients predisposed to uterine
cancer.
DRUG METABOLIZING ENZYMES, SMOKING and UTERINE CANCER:
Cigarette smoking can alter the activity of drug metabolizing enzymes like cytochromes,
which are involved in metabolizing procarcinogens. Lung cancer patients who were heavy
smokers have exhibited higher activities of aryl hydrocarbon hydroxylase (AHH) and epoxide
hydroxylase (EH) than nonsmokers. In recent smokers, AHH in lung tissue was positively
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correlated with level of tobacco smoke derived DNA adducts. Epidemiological evidence
suggests that cervix and endometrium may be differentially affected by cigarette smoking.
Differences in enzyme activity in combination with other factors like DNA repair, genetic
polymorphisms in p4501A1 enzymes (Nebert et al. 1989), HPV infections, and immunological
status of the individuals will determine the individual susceptibility to uterine cancers. There is
ample evidence suggesting that there is correlation between cervical cancer and human
papilloma virus (HPV) (Durst et al. 1983; Shiratori et al. 1987). DNA ploidy patterns were
reported to be correlated with cervical intraepithelial lesions (Bibbo et al.1989). It can be
speculated that HPV infection could be an initiating factor whereas smoking related adduct
formation could serve as promoters of the neoplastic lesions. The reduced risk of endometrial
cancer in smokers was linked to alterations in the levels of endogenous estrogens (MacMahon et
al. 1982). Therefore it was argued that reduced risk of endometrial cancer among smokers could
be due to reduced exposure to free or total estrogenic activity (Barber et al. 1989; Khaw et al.
1988). Recent evidence suggests that metabolites of estrogens such as reactive quinones
generated from catechol estrogens may act as chemical carcinogens by binding to DNA forming
DNA adducts (Li et al. 1994; Liehr et al. 1990). Therefore, it is possible to have many
confounding factors in the etiology of uterine cancer, and cigarette smoking could be one of
many such factors.
A nonspecific substrate for various CYP enzymes has been reported in uterine tissues,
which was formed by hydroxylation of cyclohexane (Senler et al. 1985). These investigators
studied only myometrium and leiomyoma conditions possibly due to the abundance of tissue
availability and incidence of clinical cases. It is therefore likely that more proliferative
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endometrial epithelium and cervical squamous and columnar cells may have measurable CYP
activity especially after being exposed to prolonged smoking, which is likely to induce the
enzyme. Recent studies revealed the role of CYP enzymes in uterine tissue especially CYP3A7,
which was observed in six out of seven cases correlating to steroid metabolism (Schuetz et al.
1993). Tissues obtained in late proliferative or early secretory phase of menstrual cycle had the
highest activity of BP binding to DNA whereas no significant difference on BP metabolites were
observed on similar evaluation of endometrial tissue cultures of smokers and nonsmokers (Mass
et al. 1981).
One of the earlier experiments involved insertion of a bee’s wax thread soaked in
3-methylcholanthrene (3-MC) into the uterus of rabbits. When inserted in a fixed position at
various sites of uterine cavity, 3-MC has shown carcinogenic effect on endometrium and cervix
(Merriam et al. 1960; Wentz et al. 1981). This suggested that the neoplastic transformation could
be due to local activation of PAHs like 3-MC by CYP enzymes.
There are other constituents in cigarette smoke like nitrosamines and other PAHs, which
are carcinogenic. However, the focus is on BP which is a more potent carcinogen and commonly
seen in the environment also. Its metabolism has attracted a great interest for investigations in
animals (Gelboin et al.1980) and in humans (Shimada et al. 1989; McManus et al.1990).
CYP1A1 and CYP1A2:

BP in cigarette smoke is metabolized primarily by CYP1A1 and

CYP1A2, which form reactive metabolites yielding covalent adducts that are likely to result in
mutagenicity. In heavy smokers, this possibility is aggravated by activating these CYP enzymes
in some tissues leading to various degree of predisposition. So, cigarette smoking not only results
in exposure to procarcinogens like BP, but also increases the levels of CYP enzymes in various
15

tissues. CYP1A2 is also significantly induced in smokers. This isozyme activates 2acetylaminofluorene (AF), 2-naphthylamine (NA), 4-aminobiphenyl (ABP) and several other
heterocyclic amines to their proximate N-oxide metabolites (Butler et al. 1989). The arylamines,
NA and ABP are also found in cigarette smoke along with BP which are procarcinogenic.
CYP1A2 is less understood than CYP1A1 because of the difficulty in studying it, owing to lack
of expression in established cell lines and rapid decrease of expression in isolated hepatocytes.
Nuclear run on analysis has indicated that induction of CYP1A2 by aryl hydrocarbons doesn’t
occur through a transcriptional mechanism but through mRNA stabilization process (Kimura et
al. 1986; Pasco et al.1988; Silver et al. 1988). The role of several CYP450 isoforms in catalyzing
the hydroxylation of cortisol, testosterone, androstendione, estradiol and progesterone has been
established (Berliner et al. 1956; Guengerich et al. 1988; Turkey et al. 1985; Lipman et al.1962).
However, it is not clear whether these reactions in the liver have any physiological importance, if
any, or simply serve as accessory elimination pathways. We have shown in our lab that the
uterus, specifically endometrium and cervix, expressed differential transcription levels of
CYP1A1 and CYP1B1 mRNA (Vadlamuri et al. 1998) and it is likely that these extrahepatic
CYP450 participate in tissue specific biotransformations which might be of physiologic
relevance.
CYP1B1:

Recently cDNA clones of mouse, rat, and human CYP1B1 have been reported

(Savas et al. 1994; Sutter et al. 1994). CYP1B1 enzyme is constitutively expressed in low levels
in many tissues including heart, brain, liver, placenta, lung, kidney, skeletal muscle, spleen,
thymus, prostate, testes, ovary, small intestines, colon, and peripheral blood leucocytes. The
enzyme was inducible by TCDD in a keratinocyte cell line. Its role in rat has been reported to be
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by oxidation of 7,12 dimethylbenz[a]anthracene (Savas et al. 1994). The human CYP1B1 was
recently characterised whose role has been suggestive in estradiol metabolism (Suter et al 1994;
Trischer et al. 1996). Recent evidence suggests that CYP1B1 may be primarily involved as E2-4hydroxylase enzyme, although the 4-hydroxylation is a minor metabolic pathway and represents
a relatively minor level of urinary catechol estrogen content (Fishman et al 1976). It has tissue
specific importance, for example the 4-hydroxylation of E2 is significant in the metabolic control
of estrogen homeostasis and in the human uterus the rate of E2-4-hydroxylation approaches or
exceeds that of 2-hydroxylation (Liehr et al. 1995). Therefore, it is likely that localized
inactivation of the estrogens in the uterus may be an important determinant in the physiological
as well as toxicological outcome. The existence of different isoforms of CYPs in various levels
in different regions, impart specificity and characterstic metabolic capacity to each organ.
Therefore, the role of these enzymes was considered important in our studies.
CYP3A group:

Existence of CYP3A enzymes in the human endometrium was reported by

Schuetz et al. (1993) through positive reactivity on immunoblots with antibodies of CYP3A7.
However very little CYP3A3/4 was observed in the endometrial tissues. The catalytic specificity
of estradiol has not yet been established, however similar to other CYP3A enzymes, CYP3A7
mediates testosterone 6 β –hydroxylation. CYP3A7 has been found to catalyze 16 α hydroxylation of dihydroepiandrosterone to estrogen. This finding adds a new dimension to
etiology of endometrial carcinoma since high levels of CYP3A7 will result in increased
estrogenic exposure which is likely to predispose the individual to development of endometrial
cancer. Recently CYP3A7 and CYP3A4 were observed in endometrial tissues where they
induced DNA adduct formation during tamoxifen therapy (Hukkanen et al. 1998). In a study
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conducted by Environmental Epidemiology branch of National Cancer Institute, it was reported
that the relative risk of cervical cancer in heavy smokers is about four times as great than that of
nonsmokers (Brinton et al. 1986). The mucus obtained by cervical washing from smokers was
tested to be mutagenic in in vitro testing (Holly et al. 1986). Further, in smokers with
intraepithelial neoplasia, levels of nicotine and its major metabolite cotinine, both of which are
present in cigarette smoke, were detected in cervical mucus at levels similar to those seen in
serum (Hellberg et al. 1988). This evidence confirms that some chemicals and metabolites
present in cigarette smoke reach distant organs in the body like the cervix. The evidence that
BPDE-DNA adducts are seen in squamous cells of patients with invasive cervical carcinoma
indicate that BP in cigarette smoke reaches the uterus (Shamsuddin et al. 1988). Although there
is vast evidence correlating HPV infection with cervical cancer, the population studied didn’t
include smokers. Recent papers suggest that HPV may be less of a risk factor than once thought
(Reeves et al. 1989). Thirty percent of patients who were tested negative for HPV had high-grade
cervical intraepithelial neoplasia compared to 15% who were HPV positive. This implies that
there is a mechanism, other than HPV, which is important in cervical cancer. It could be
possible that a pro carcinogenic mechanism was initiated first and then neoplastic transformation
was done with the help of HPV. A similarity could be drawn for this hypothesis with the
findings of 1938 where malignancy was experimentally induced with exposure of benign lesions
to papilloma virus. It was shown that coal tar induced benign skin lesions in rabbits which were
rapidly converted into malignant tumors when rabbit papilloma virus was given by intravenous
injection (Rous and Kidd 1938). Therefore, if the cells in cervical squamosa respond to
carcinogens like BP from cigarette smoke, as the cells in lung, a similar mechanism could exist
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for both cervical and endometrial cancer. There is evidence that women who smoke reach
menopause earlier than those we don’t (Daniell et al. 1978). Also, decreased levels of
endogenous estrogens in smokers imply that reduced incidence of endometrial cancer could be
due to reduced tissue exposure to total estrogenic activity (Barber et al. 1989; Khaw et al. 1988).
This is further supported by epidemiological data on increased risk of endometrial cancer among
the users of conjugated estrogens (Ziel et al. 1975). The role of estrogen receptors has yet to be
investigated since estrogen receptor antagonists like tamoxifen used in breast cancer patients
didn’t limit the incidence of uterine cancers, particularly endometrial cancers (Fornander et al
1989; Spinelli et al. 1991). Therefore, it is likely that other mechanisms may contribute to
endometrial cancers.
CYTOCHROME P450, ESTROGEN METABOLISM and UTERINE CANCER:

The metabolic

pathways of estrogens reveal that CYP 450 enzymes are involved in various stages of menstrual
cycle through hydroxylation reactions. The CYP dependent hydroxylations produce inactive
catechol estrogens such as 2-hydroxy estradiol or estrogen agonist like 16α hydroxyestradiol
(Michnovicz et al. 1986). In humans estradiol metabolism is primarily mediated by CYP1A2
(Dannan et al. 1986) and to a lesser extent by CYP1A1 and CYP3A4 (Guengerich et al. 1987;
Roy et al. 1991). There is evidence that 16 α hydroxylation has correlation with cases of
endometrial cancer (Fishman et al. 1984). Increased 2-hydroxylation is linked to reduced risk of
endometrial cancer (Michnovicz et al. 1986). These findings suggest that shunting the estrogenic
pathway in such a way that reducing 16 α hydroxylation and in turn increased 2-hydroxylation
by CYP1A2 and CYP3A4, could possibly reduce the risk of endometrial cancer. It was shown in
rats that 2-hydroxy estrone gets converted to 2, 3 estradiol quinone, which binds tightly to
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CYP1A1. This binding results in elimination of Ah hydroxylase activity in kidney as reported by
Roy et al. in 1991. So, if the endometrium behaves like kidney, BP activation through CYP1A1
is likely to be bypassed because formation of BPE, a procarcinogen, is not accomplished. These
CYP enzymes have in particular links with estrogen metabolism. The smokers have shown a
marked increase of 2- hydroxylation of estradiol in liver (Michnovicz et al. 1986). This
hydroxylation was modulated by CYP1A2 (Dannan et al. 1986) and also by CYP1A1 (Roy et al.
1991) and CYP3A4 (Guengerich et al. 1988). During a reversible metabolic pathway, estradiol
produces 2-hydroxy estrones and 2-methoxy estrones or 16 α hydroxyestrone and estriol. These
possess potent estrogenicity (Michnovicz et al. 1986). The 2-hydroxylation of estrogens are
devoid of peripheral estrogenic activity and high levels of estrogens in plasma are linked to
endometrial cancer (Fishman et al. 1984). Therefore, smokers who have excessive 2hydroxylation might be showing reduced incidence of endometrial cancer. Recent evidence
suggests that 2-hydroxylated metabolites could be converted to quinones, which inactivate
CYP1A1 at least in hamster kidney (Roy et al. 1992). The CYP3A4 which has a wide substrate
specificity was implicated in activation of hepatocarcinogen like aflatoxin, so this isozyme may
have an active influence along with other CYPs. Estrogens were the main driving force for
carcinogenesis with progestins reversing or preventing some of these changes (King 1983) as
shown below in the Figure 2.2.
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Figure: 2.2 Estrogen and Progestin impact on metastasis (king et al. 1983).
Increased proliferation assists in generation of errors such that genetic changes are
accelerated (Loeb et al. 1994; Eshleman et al.1995). Estrogens induce apoptosis in the
endometrium. Any disruptive change can disturb this link. A pivotal gene linking proliferation
and apoptosis is p53 gene, which was inactivated in 20% of endometrial carcinomas (Homesley
et al. 1994). As menstruation is a consequence of progesterone production and withdrawal,
inadequate menstrual loss could explain some more risk factors. Estrogens sensitize the cells to
progestin action by increasing PR levels, while progestins downregulate estrogen effects by
decreasing ER levels through increasing the catabolism of estradiol by induction of estradiol
dehydrogenase and differentiation (King et al.1983). Both estrogens and progestins influence
proliferation via their own receptors, which are nuclear transcription factors (King et al. 1992)
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Cervical carcinoma is a sporadic cancer for which no familial form has yet been
identified, and which so far has not been associated with any inherited syndrome. Loss of
heterozygosity (LOH) in primary cervical carcinomas was initially reported on chromosome 3 in
the region 3p14-21 in a small series of nine heterozygous cases (Yokota et al. 1989). A common
region of deletion was identified at chromosome 3p13-14.3 with 6 out of 7 cases showing loss of
heterozygosity at this region. Chromosome 11 holds promise of another tumor suppressor gene
important in cervical carcinomas. LOH has been described in 36% of cases at c-Ha-ras locus on
chromosome 11p (Riou et al. 1988). Similarly there could be involvement of other tumor
suppressor genes in cervical cancer which calls for further investigation.
There are in vitro studies of DNA adduct formation in endometrial cells, which are
influenced by hormonal status (Dorman et al. 1981). Cigarette smoke contains many pro
carcinogens like PAHs (BP) which are strongly implicated in cancer incidence. Other substances
like nitrosamines and 4-methyl nitrosamino-1- (3-pyridyl)-1-butanone (NNK) are also present in
significant levels among other 50 or more carcinogens present in tobacco smoke. BP is 200
times more potent than the other carcinogens (Lavoie et al. 1987; Hecht et al.1988). The
proposal to study in controlled environment with animal models is not feasible due to the small
size of uterus, and thereafter, small amounts of tissues in various regions of uterus render such
studies virtually impossible. Further menstruation is unique to primates and in laboratory models
we miss this regulatory mechanism which might elicit an important mechanism. The mechanism
of BP causing cancer can’t be established by direct studies in humans. However indirect
evidence suggests the BP activation can initiate carcinogenesis. 100% of animals receiving low
intravenous doses of BPDE developed tumors in lung (Conney et al. 1982).
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There is ample evidence that smoking is associated with lung cancer in humans. AHH
activity as a measure of CYP1A1 was found to be high in smokers and its association with
peripheral adenocarcinoma of lung was well established (Anttila et al. 1991). Smokers have
shown greater BPDE-DNA adducts which are suggestive of carcinogenic precurssors (Geneste et
al. 1991). The smokers with homozygous rare allele of CYP1A1 locus exhibited higher risk for
lung cancer in comparison with other genotypic combinations (Kawajiri et al. 1990). Therefore,
based on the similar mechanism of lung cancer we would like to evaluate the genetic make up of
uterine cancer with respect to toxicological activation by CYP enzymes especially CYP1A1, 1B1
and 3A3/3A4 and or 3A7. The relative abundance of these important isozymes will be studied in
designated regions of uterus among smokers and nonsmokers.
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DESCRIPTION OF PROBLEM
It was widely reported that cervical cancer is predominantly seen among women with a
history of prolonged smoking whereas the incidence of endometrial cancer is decreased by
almost 50% in post-menopausal women who are smokers. These two regions - endometrium and
cervix, are less than 10 cm apart in the same organ yet exhibit different carcinogenic property.
This differential disposition could be explained through metabolic pathways of cytochrome P450 (CYP). Some of these CYP s activate chemical carcinogens to their electrophilic forms
which can bind to DNA covalently and cause mutation that trigger carcinogenesis. Among the
various CYP s, CYP1A1, CYP1B1, and the CYP3A family are primarily implicated due to their
metabolic pathways involving polycyclic aromatic hydrocarbons such as benzo (a) pyrene,
estrogens, steroids etc. Therefore, the goal of the study was to investigate the expression of these
CYP isoforms in different regions of the uterus among smoking and nonsmoking women.
BP as already known, is usually metabolized by CYP enzymes - CYP450 1A1 and 1A2
(Figure 3.1). We propose that BP, the potent procarcinogen present in cigarette smoke, gets
transported to many tissues in the body including uterus. It gets metabolized into BPDE through
metabolizing enzymes such as CYP1A1 and CYP1A2 and CYP3A3/A4 in various tissues such
as lungs, uterus, etc. The BPDE, thus available in some parts of uterus, is likely to bind to DNA
in the various regions of uterine tissue, which can cause mutation or activate oncogenes.
The proposed scheme of BP metabolism relevant to our hypothesis is given in the following
diagram as shown in the NCI grant # CA-62369 by Mohamadi A Sarkar.
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Figure: 3.1 Proposed Biotransformation scheme for Benzo(a)pyrene (BP) (Mohamadi A
Sarkar, 1992. NCI grant # CA-62369)
CYP enzymes also are involved in estrogen metabolism. These enzymes have an active
role in endometrium especially where role of estrogen was predominantly seen. We propose the
scheme of estrogen metabolism, which is likely to trigger carcinogenesis in uterus in the
following diagram:
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Figure: 3.2 Proposed metabolic scheme for estrogens modified from Yager et al (1996)

The CYP enzymes like CYP1B1 and CYP3A group (especially CYP3A3/4 and
CYP3A7) are actively involved in estrogen metabolism. These enzymes also indirectly influence
the carcinogenicity through estrogen mediated pathway. The metabolites of CYP enzymes are
hydrophilic which can conveniently form covalent structures with DNA if not excreted fully. The
DNA is in active state of multiplication in uterus due to cyclic changes. This offers an immediate
possibility to influence tumorigenesis.
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In heavy smokers the problem of over expression of CYP enzymes contribute to the
formation of excessive reactive metabolites possibly due to excessive release of BP into tissues
and accelerated CYP activity. There is ample evidence showing that free estrogens contribute to
incidence of breast cancer. The cytochrome mediated metabolism of estrogens releases free
catechol estrogens. Therefore sensitive tissues in uterus get exposed to these estrogens which are
likely to contribute to neoplastic transformations.

HYPOTHESIS:
The levels of one or more of CYP enzymes were involved in the activation of benzo (a)
pyrene which may be causing the increased risk for cervical or endometrial cancer. Smoking
induces the activation of CYP1A1 and /or CYP1A2, which may be a major cause of cervical
cancer. Induction of those isozymes might decrease the risk of endometrial cancer due to
decreased estrogenic activity, which was known to be a risk factor in endometrial cancer.
AIMS:
1. To investigate and identify the Cytochrome P- 450 expression viz.: CYP1A1,
CYP1B1, and CYP3A group in the endometrial, endocervical and/or squamous cell
regions (exocervix) of human uterus.
2. To evaluate the intensity of expressions at mRNA level in various regions of the
uterus.
3. To analyze the expression levels of CYP1A1, CYP1B1, CYP3A3/A4 and CYP3A7 in
women at various phases of their menstrual cycle.
4. To assess the significance and differentiate expressions among smokers and
nonsmokers.
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Materials and Equipment used:
The list of materials, equipment and buffers used are given in Appendix: D.

Methods:
The protocol involving collection of tissue samples from patients was approved by the
West Virginia University Institutional Review Board. The uterine tissue samples were collected
from women undergoing hysterectomy for various benign clinical conditions. Clinical history and
other demographic details were obtained from clinical records. The format employed to collect
data is presented in Appendix: E.

1. Tissue Procurement
Uterine tissue was obtained initially from six non-smoking pre-menopausal women
undergoing hysterectomy for benign indications. The tissues were collected within 30 minutes of
surgery, from three different regions of the organ, carefully sectioned to maintain sampling
consistency. The endometrium was obtained by scrapping the posterior surface of the inner
lining of the fundus of the uterus. A thin layer of tissue was excised from the cervical canal at
6’o clock position, to include the endocervix and squamocolumnar junction. The ectocervix or
squamous (exocervix) region was sectioned from the anterior region of the cervical. The tissues
were collected in separate containers and stored immediately at -700C.
The quantities of samples collected are shown in the Figure 4.1

30

Size of tissue obtained after sampling from a
typical uterus
Typical scrapping of
endocervix
Typical section of
myometrium

Typical scrapping of
endometrium

Figure: 4.1 Tissue sampling procedure
Initially the samples were collected from six patients and RNA extraction was done.
Subsequent to analyzing these samples for the expression of CYP1A1 and CYP1B1 and
optimizing the PCR protocols, tissue procurement continued for a total of 36 patients in a similar
fashion over a period of 2 years. The limitation of obtaining tissue samples from clinical
subjects was compounded due to competitive requirements of tissues for pathological studies,
clinician’s preferences and patient willingness.
2. RNA Procedures
RNA extraction
Total RNA was extracted from the tissues by homogenizing the tissue in liquid nitrogen
and quickly transferring to 3 ml of RNA STAT-60 (Tel-Test inc., Friendswood, TX) reagent. A
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standard extraction protocol involving RNA STAT-60 kit was used, yielding 50µg - 100 µg
RNA from 50-300 mg of tissue.
RNA quantification
RNA concentrations were measured at 260nm on a Beckman UV spectrophotometer and
the Abs 260/280 was >1.5 for all samples. The procedure to operate the UV spectrometer was as
per the manual. The RNA concentrations were calculated after adjusting to the dilutions used in
measuring the absorbance. The final concentrations of the samples are provided in Table in
Appendix: F.
RNA quality analysis
The extracted RNA was run on 1.2% agarose formaldehyde denaturing gel
electrophoresis to check the quality of RNA isolated. The quality of RNA was checked for DNA
contamination, degradation due to RNases and also visual verification of 28S and 18S bands.
3. Reverse - Transcription polymerase chain reaction (RT-PCR) of CYP mRNAs
cDNA was synthesized in a total volume of 20 µl of reaction mixture containing 2µg of
total RNA in the reverse transcription reaction buffer (Gibco-BRL, Gaithersburg, MD), 10mM
DTT, 25 µg/ml of oligo(dT), 0.5mM of each dNTP, 25 mM MgCl2 and 200 units of M-MLV
reverse transcriptase (Gibco-BRL). Samples were incubated at 420C for 50 min and the reaction
was terminated by heating at 950C for 5 min., followed by quick chilling on ice. Target
sequences were amplified in a 100 µl reaction mixture containing 15µM of each primer, and 5
units of Taq polymerase (Promega Corporation). After addition of 100µl of mineral oil in PCR
tubes (0.5ml), preincubation for 5 min at 950C was carried out followed by thirty cycles of
amplification using a thermal cycle program consisting of 940C for 30 sec of denaturation, 620C
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for 30 sec annealing, and 720C for 1 min of extension on Perkin Elmer - Thermal Cycler system 480. The PCR products (15 µl) were directly separated through 2% agarose gel electrophoresis
and visualized by ethidium bromide staining. Sizes of the PCR products were estimated from the
migration of the DNA size markers (2000 kb ladder - BioRad) run concurrently.

4. Semiquantitaive Analysis:
Densitometric analysis was carried out on those gels where PCR products were resolved
using an image analysis (Optimas) software. Care was taken to follow uniform conditions
throughout and to observe the same settings on the threshold values, microscopic lens, gel
thickeness, quantity of PCR product loaded and other parameters. The quantitative values were
further corrected/adjusted with the actual amount of mRNA used initially in the reaction.
Control RNA (891-bp CAT derived) was included to verify the PCR reaction. The
quality of RNAs was evaluated through the expression of β−actin gene. The primers for β−actin
were obtained from Clonetech (Palo Alto, CA). β−actin was positive for all tissue samples.
Contamination with genomic DNA was ruled out from the negative results obtained when the
RT-PCR was performed without the reverse transcriptase.
The quantity of the PCR product was measured as a ratio of its optical density with that
of house keeping gene – β- actin from same RNA. β- actin was amplified with same conditions
and same amount of mRNA. The β- actin expression was optimized before quantifying in a
similar way to amplified CYP1A1 and CYP1B1 genes.
The sequences of primers used for the PCR reaction have been identified and used by
other researchers, therefore no further confirmation of the PCR product was considered
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necessary initially. However in subsequent experiments the PCR products were confirmed by
hybridizing with internal oligos of the PCR product.
5. Primers
Sequences utilized for the preparation of forward (FP), and reverse (RP) PCR primers
were as follows:
*CYP1A1:

**CYP1B1:

*
**

FP: 1729-1749:

5'-TAG ACA CTG ATC TGG CTG CAG - 3'

RP: 1856-1875:

5'- GGG AAG GCT CCA TCA GCA TC - 3'

FP: +1758 - +1777

5' - AAC TGT CCA TCA GGT GAG GT - 3'

RP: +2227 - +2248

5' - TAA GGA AGT ATA CCA GAA GGC - 3'

Shimada, T. et al. 1989
Denissenko, M. F. et al. 1996.

6. Endometrial dating – proliferative and secretory endometrium
The endometrial dating was accomplished by a pathologist, using a light microscope,
according to the technique of Hertig and classified as either proliferative or secretory.

7. Patient Demographics:

Patient ages ranged from 25-78 years and weight from 112-277 pounds (Tables 1 and 2).
None of the patients were taking medications that could potentially induce CYP450 activity.
Seven of the twenty-two patients had uterine leiomyomata (fibroid uterus) and 5 patients had
endometriosis. Three patients had endometrial hyperplasia, one patient had adenocarcinoma of
the endometrium and one patient had Stage I - Squamous carcinoma of the cervix. Additionally,
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one patient (ID # 10) had previously been treated for CIN III with a cone resection. In the
patient with cancer, an attempt was made to obtain tissues from non-neoplastic regions if the
tumor area was visibly discernable.

8. Titration Analysis to determine linearity for sample comparison:

Serial dilution of cDNA was performed and the diluted cDNA was amplified by PCR.
The PCR products exhibited excellent linearity (r2=0.97) over a concentration range of 0.6 - 0.75
µg/µl. The correlation was evaluated by comparing the optical density of the PCR product,
using densitometric analysis, with relative amounts of mRNA determined from the serial dilution
of cDNA.

9. Probes:
The probes used to confirm the PCR products were oligos identified from internal
sequences of the amplified fragment. The sequences are 18 nt and 17 nt long from antisense
strand in the coding region of CYP1A1 and CYP1B1, respectively.
Probe for CYP1A1: 5'- TAG GGG CAG GCA GGA TCC-3' (1780-1798)
Probe for CYP1B1: 5'- CTC CCA GAA GCT CCT GC - 3' (2509-2526)
10. Southern Blot analysis:
PCR products were analyzed by electrophoresis with ethidium bromide staining on 2%
agarose gel with TBE buffer. The DNA markers (Bio-rad) were loaded to assess the sizes of the
fragments. After electrophoresis the gels were denatured and blotted to Zeta probe Nylon
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membrane (Bio-rad) with 10x SSC overnight. Other sets of blots (transfer membranes) were
also prepared where transfer was done by alkaline transfer method using 0.4N sodium hydroxide
solution. Membranes, except those done by the alkaline transfer, were cross linked by a UV cross
linker (Stratagene). Membranes were prehybridized for one hour at 420C for CYP1A1 and 380C
for CYP1B1 probes. Hybridization was accomplished overnight at 420C and 380C for CYP1A1
and CYP1B1, respectively, in the presence of formamide 50%, SDS 7%, 1M of Na2HPO4 25%,
5M NaCl 5%, 0.5M EDTA 0.2% and Salmon sperm DNA (1mg/ml solution) 1% in final
concentration. After hybridization, the membranes of CYP1A1 were washed twice with
solutions containing 2xSSC, 0.1%SDS at 360C for 15 minutes. This step was followed by a low
stringency wash with 0.1%SDS, 25mM Na2HPO4and 1mM of EDTA at 290C for 15 minutes
twice and by high stringency wash once for 20 minutes at 420C. Whereas for membranes of
CYP1B1 the washes were done at 300C for 15 minutes twice with buffer containing 2xSSC,
0.1%SDS followed by one wash at room temperature for 15 minutes with 0.1%SDS, 25mM
Na2HPO4 and 1mM of EDTA. The probes were found to hybridize with PCR fragments, which
were detected by exposing the membranes in overnight Phosphor-imager screen.
11. Expression of CYP3A group of isozymes:
CYP3A isozymes have 60 – 80% homology among all the members of the group. As a
result, for the individual CYP3A, false positives and cross reaction with primers could not be
completely eliminated. Further, the specificity of the primers for single isozyme can not be
established in view of the close homology between members of CYP3A and individual variation
among patients is also random. To circumvent this difficulty in expressing the CYP3A isoforms
we adopted an approach as suggested by Dr. Thomas A Kocarek, Institute of Chemical
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Toxicology, Wayne State University, MI. Accordingly, a set of common primers was designed
using software and the CYP3A was amplified from the mRNA. These primers were common to
all CYP3A family of isozymes and as a result any one or two isozymes were amplified if present.
The amplified PCR products were transferred to Zeta probe Nylon membranes and tested with
individual probes of CYP3A3/4, CYP3A7 isozymes. CYP3A3 and CYP3A4 have 90%
homology in human sequences and exhibited similar induction pattern. Hence we considered
one probe for CYP3A3/4 isozyme. The sequence alignment and identification of the forward and
reverse primers are given in the Figure 4.2.

FP: Forward primer
RP: Reverse primer
Figure: 4.2 CYP 3A group sequences are aligned as obtained by using computer program.
Forward primer and Reverse primer locations are identified and marked as FP and RP.
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12. Primer Design for CYP3A group of isozymes:
As shown in Figure 4.2, sequences of all human CYP3A isozymes were aligned using a
software and examined for common overlapping sequences.
The 619 to 636 nt region and 1055 –1072 nt region among all the CYP3A sequences are
common.

Primers
Sequences utilized for the preparation of forward (FP), and reverse (RP) PCR primers
were as follows:
CYP3A
FP: 619-636:

5'- GCC TAC AGC ATG GAT GT - 3'

RP: 1055-1072:

5'- TGG ACA TCA GGG TGA GT - 3'

The specific probes for the CYP3A3/4 and CYP3A7 were identified from the sequences aligned.
Probes
The probes utilized for hybridization were as follows:
CYP3A4 :
759-779

5' - CTT AAA AAA TTT GTA ACT TC - 3'

CYP3A7 :
642-662

5' - CGA ATG GAT CTA ATG GAT TA - 3'
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13. Reverse - Transcription polymerase chain reaction (RT-PCR) of CYP3A mRNAs
The PCR reaction was carried out using the consensus primers for CYP3A in the region
of 619 nt to 1072 nt. The target complimentary DNA (cDNA) was synthesized from total RNA
by RT-PCR reaction catalyzed by superscript II RNase H - reverse transcriptase (RT)
enzyme(Gibco-BRL) carried out in a Perkin Elmer - Thermal Cycler system - 2400. First strand
cDNA was synthesized in a total volume of 20µl of reaction mixture containing 2µg of total
RNA in the reverse transcription reaction buffer (Gibco-BRL, Gaithersburg, MD), 10mM DTT,
25 µg/ml of oligo(dT), 0.5mM of each dNTP, 25 mM MgCl2 and 200 units of M-MLV reverse
transcriptase (Gibco-BRL). Samples were incubated at 420C for 50 min and the reaction was
terminated by heating at 950C for 5 min., followed by quick chilling on ice. The reaction samples
were further incubated with 100 units/ml of RNase H for 20 minutes at 370C. Target sequences
were amplified by hot start PCR at 940C in a 20µl reaction mixture containing 2µM of each
primer and 1 unit of Taq polymerase (Promega). The sample tubes (0.2ml) were preincubated at
940C for 1 min before the addition of Taq polymerase and followed by forty cycles of
amplification using a thermal cycle program consisting of 940C for 20 sec of denaturation, 540C
for 20 sec of annealing, and 720C for 1 min of extension. The PCR reaction products (10 µl)
were separated through 2% agarose gel electrophoresis and visualized by ethidium bromide
staining. Sizes of the PCR products were estimated from the migration of the DNA size markers
(2000 kb ladder - BioRad) run concurrently.
Control RNA (891-bp CAT derived) was included to verify the PCR reaction. The
quality of the RNA was examined by electrophoresis of 5µg RNA in 1.2% denaturing agarose
gel (formaldehyde gel) and also evaluated through the expression of β-actin gene. The primers
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for β-actin were obtained from Clonetech (Palo Alto, CA). β-actin was positive for all tissue
samples. Contamination with genomic DNA was ruled out from the negative results obtained
when RT-PCR was performed without the reverse transcriptase. Direct sequencing of PCR
products did confirm the target sequences with 99% accuracy with a 1% base pair mismatch.

14. Hybridization analysis:
The method as given in current protocols (Frederick et al. 1987) was followed with
some modifications. After electrophoresis the gels were denatured and blotted to Zeta probe
Nylon membrane (Bio-rad), where transfer was done by alkaline transfer method using 0.4N
sodium hydroxide solution. Membranes were hybridized with the specific internal probes for
CYP3A3/4 and CYP3A7.
The probes were obtained from Gibco-BRL and end labeled at the 5' end with γ 32-P
dATP (Redivue - Amersham) using 5'-End labeling system (Promega). The probes were
made with 10 pmoles of oligo incubated with γ- 32P ATP and T4 polynucleotide kinase in 1x
forward reaction buffer at 370C for 30 minutes. The reaction containing the probes were
purified by separating the unincorporated oligos with G-50 Sephadex columns (Boehringer
Mannheim ). The specific activity obtained for the probes was 137000 cpm to 156000 cpm
per 10 pmoles as measured in a scintillation counter.
The membranes were transferred to hybridization flasks without any air bubbles
between the membranes and wall of the glass flasks. These membranes having the CYP3A
products were initially prehybridized with hybridization buffer at 650C for 2-4 hours. Then
the membranes were incubated overnight with probes (25µl final volume) in 8ml of
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hybridization buffer. The hybridization and washes were undertaken in hybridization oven
(Stovall).
Wash solutions included wash buffer containing 5X SSC, and 0.1% SDS which was
used for 15 min at 340C, followed by buffer II containing NaHPO4 25mM, EDTA 1mM, SDS
0.1% at 29.50C for 15 min. A final wash was done with buffer II above at room temp for 15
minutes. The probes were found to hybridize with PCR fragments, which were measured
after overnight exposure of the membranes on a Phosphor-imager screen.

15. Reconfirmation of the probe specificity:
The probes were stripped from the respective membranes by incubating in warm (370C)
stripping solution containing 20% SSC until the buffer attained room temperature. The
membranes were then hybridized by interchanging the probes and evaluated as to the relative
intensities of expression of 3A4 and 3A7 on the membranes. This process eliminated the
possibility of any non-specific hybridization, and confirmed that the expression levels of 3A4
and 3A7 remained similar after interchanging the probes on the same membranes to that of
different membranes.
16. ImageQuant Analysis:
The relative abundance of hybridization was measured by using ImageQuant software
under uniform parameters of equal area, pixels, color intensity values etc., after correcting for
background intensity with relative areas at the same lane of fragment movement in respective
gels. The values generated were analyzed using JMP software (SAS Institute, NC).
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17. Data Analysis:
Statistical analyses were carried out using JMP Software (SAS Institute, NC).
Comparisons were made using a multi-factor analysis of variance. The values of density of the
probe as measured in a phosphor imager were adjusted to that of initial mRNA concentrations
and then as a ratio of its density with that of housekeeping gene - β - actin from the same RNA.
β - actin was amplified with the same conditions and same amount of mRNA. The differences in
optical density of probes as obtained by computerized image analysis were evaluated between
different regions of the uterus with respect to smoking status and menstrual phase.
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CHAPTER

RESULTS

5

RESULTS

1. Expression of CYP1A1 and CYP1B1 in nonsmokers:
The patient demographics are shown in Table 1 for the first six patients used as a model
to analyze the expression of CYP1A1 and CYP1B1 among nonsmokers. The findings have been
published in Cancer Letters 122, (1998), pp 143 –150.
The age of the patients ranged from 37-48 years and weight ranged from 135-277 lbs.
None of the patients were on any comedications that could potentially induce CYP450 activity.
Four of the six patients had uterine leiomoyma and all except one patient were in the
proliferative phase of their menstrual cycle.
The expression of CYP1A1 and CYP1B1 in different regions of the human uterine tissue
is shown in Figures 5.1 and 5.2 respectively. The transcripts encoding CYP1B1 were uniform in
the endometrial region for all the patients except one where it was significantly decreased
(p<0.05). The endometrium in this patient was in the secretory phase, whereas all the other
endometrial tissues were in the proliferative phase. The transcripts encoding for CYP1B1 were
significant in only 2/6 patients in the squamous region (exocervix) and minimal in the
endocervix. The expression of CYP1A1 appeared to be increased in one patient (Pt. #3) in all
three regions, yet the patient history did not give any indications to suggest enzyme induction.
The same patient also had induced levels of CYP1B1 mRNA in the squamous region (exocervix)
and endocervix. A semi-quantitative analysis of the optical density of the RT-PCR products by
densitometry yielded results as shown in Figure 5.3. The endometrium appeared to have the
highest degree of transcripts encoding for CYP1B1 whereas the endocervix had the least
expression of both the isoforms.
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2. Expression of CYP1A1 and CYP1B1 in Nonsmokers and Smokers and with respect to
Menstrual phase:
Transcripts encoding for CYP1A1 and CYP1B1 mRNA were observed in different
regions of the human uterus as shown in Figures 5.4 and 5.5 respectively. The demographics of
all the 22 patients for this analysis is given in Table 2. The measured levels of CYP1A1 and
CYP1B1 for all patients are given in Tables 3 and 4. There were no differences in β-actin mRNA
levels for each sample (data not shown), confirming that equal quantities of mRNA were used in
all analyses. CYP mRNAs detected in samples stored at -70o C (stored for less than 3 months)
were comparable to those extracted from fresh samples. Electrophoretic mobility of the PCR
products was at the expected molecular weights in all samples, enabling comparison of relative
expression of mRNAs in the different regions from each individual. The transcripts of these two
CYPs in all the three regions of uterus among nonsmokers and smokers are shown in Figures 5.6
(endometrium), 5.7 (Cervix) and 5.8 (Squamous region). No difference for CYP1A1 mRNA
expression could be observed in the three regions when compared to proliferative or secretory
phases of menstrual cycle.

CYP1A1 and CYP1B1 in the Endometrium:
CYP1A1 (Figure 5.4) and CYP1B1 (Figure 5.5) were expressed in the endometrium of
all patients except Pt. #10 whose endometrium was hyperplastic. CYP1A1 was expressed in the
endometrium of all except one patient but expression was minimal in other regions.
Expression of CYP1B1 was significantly higher in endometrium and extremely low in secretory
stage of menstrual phase. Densitometric analysis of the CYP1B1 PCR product relative to β-actin
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mRNA indicated a 20-fold greater level of CYP1B1 expression (Figure 5.12) in proliferative
endometrium compared to secretory endometrium which was statistically significant (p<0.05).
Comparison of CYP1B1 expression in the endometrium from smokers and nonsmokers indicated
an apparent reduction in the mRNA coding for CYP1B1 in smokers which was not statistically
significant (Figure. 5.11). This difference could be confounded due to a preponderance of
secretory endometrium in the smoker group (6/11). The apparent differences in CYP1B1
expression for proliferative endometrium remained significant, even after separating the smokers
from the nonsmokers. On the other hand, no significant differences in mRNA for CYP1A1
(p>0.05) were observed in the endometrium from smokers compared to nonsmokers (Figure 5.9)
and when comparing the proliferative to the secretory endometrium (Figure 5.10).

CYP1A1 and CYP1B1 in the Cervix:
The mRNA levels for CYP1A1 and CYP1B1 were variable in both smokers and
nonsmokers (Figures 5.4, 5.5 and 5.7). While 3/11 nonsmokers did not have measurable levels
of CYP1A1 mRNA, detectable levels were observed in every smoker. An apparent 12-fold
induction in the CYP1A1 mRNA levels was observed in the smokers compared to nonsmokers
(Figure 5.9), and one of the smokers had the highest level of mRNA of all the patients. Overall
the levels of CYP1B1 mRNA were lower in the cervix, with none being detected in 11/22
patients, 5 of which were smokers and 6 nonsmokers (Figure 5.11). No differences could be
observed in the expression of the two isoforms in the cervical tissue obtained from patients with
secretory and proliferative endometrium (Figure 5.12).
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CYP1A1 and CYP1B1 in the Squamous (exocervix) Region:
CYP1B1 mRNA was not detectable in the squamous (exocervix) region of smokers
(Figure 5.8) and only 2/11 nonsmokers had measurable levels, albeit Pt.#3 had significant
expression (Figure 5.5).
CYP1B1 expression appeared to be lower in smokers by 3-fold. Poor expression of
CYP1A1 was also seen in the nonsmokers compared to smokers.

Approximately a 2-fold

induction of the CYP1A1 mRNA was apparent in smokers compared to nonsmokers (Figure
5.9). Patient #3 had significant expression of both CYP1B1 and CYP1A1 in this region,
however her history was not suggestive of enzyme induction.

3. Expression of CYP3A3/A4 and CYP3A7 in Endometrium and Cervix:
The patient demographics are shown in Table 5. The measured levels of CYP3A3/A4 and
CYP3A7 as ratios with respect to β actin levels are given in Table 6. The age of the patients
ranged from 25-48 years and weight ranged from 112-277 pounds. None of the patients were on
any comedications that could potentially affect CYP450 levels, specifically the patient charts
were evaluated for any drugs that could likely induce CYP3A isoforms e.g. rifampin or rifabutin.
The endometrial tissue was classified as either in the secretory or luteal phase (n=15) and
proliferative or follicular phase (n=19). Two patients not included in the table did not have any
measurable CYP3A consensus primer RT-PCR product and therefore could not be processed for
hybridization.
Initial probing evaluation with the consensus CYP3A primers illustrated measurable
CYP3A expression in the cervix as well as the endometrium (Figure 5.13), however the intensity
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was visibly lower in the endometrium (Figure 5.14) compared to the cervix (Figure 5.15). The
expression of CYP3A4 and CYP3A7 in different regions of the same representative human
uterine tissue is shown in Figures 5.14 and 5.15, respectively. The transcripts encoding for
CYP3A7 appear to be higher in endometrium obtained from patients in the proliferative phase
(Figure 5.16) of the menstrual cycle compared to secretory phase (Figure 5.17). The CYP3A4
mRNA appeared to be comparable between the two phases. A semi-quantitative analysis of the
autoradiography by the ImageQuant software yielded relative intensities, which were compared.
The expression of CYP3A4 and CYP3A7, as measured by the relative abundance of
hybridization, were much higher in the endometrium compared to the cervix (Figures 5.18 and
5.19). No difference in expression of CYP3A3/3A4 was observed in different stages of
endometrium. The endometrium from the patients in proliferative phase had the maximum
CYP3A7 expression levels (Figure 5.18), which was significantly greater than the secretory
phase (p<0.05).

The relative intensity of hybridization for CYP3A4 in the endometrium

appeared to be similar between the phases of the menstrual cycle (Figure 5.18).

4. Expression of CYP3A3/A4 and CYP3A7 in Nonsmokers and Smokers:
A 30fold decrease of CYP3A3/3A4 was observed among smokers than nonsmokers in
secretory phase of endometrium. Expression of CYP3A7 was increased 17-fold in proliferative
stage than in secretory phase in endometrium. A 40-fold and 20-fold higher expression of
CYP3A7 and CYP3A3/3A4 were observed in proliferative to secretory phase endometrium in
smokers (Figure 5.21b). No significant difference was noticed for either isoforms in different
menstrual phases among overall comparison of smokers and nonsmokers.
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There is no significant difference (p>0.5) among smokers and nonsmokers in the
expression of CYP3A3/A4 in endometrium (Figure 5.20). In endometrium the expression of
CYP3A7 is also not significantly different (p> 0.08) in smokers and nonsmokers (Figure 5.21).
In cervical region (Figures 5.22 and 5.23) also the expression of these isozymes is not
significantly different between smokers and nonsmokers (p>0.4 for CYP3A3/A4 and p>0.3 for
CYP3A7). The expression of CYP3A3/A4 and CYP3A7 in endometrium and cervix for
nonsmokers and smokers is given in Figures 5.24 and 5.25, respectively. The results of
CYP3A3/A4 and CYP3A7 were analyzed statistically with interactions and without interactions
(Appendices D.2 to D.5). Models were analyzed between CYP3A3/A4 and CYP3A7 with the
differences from that of relative expression between smokers and nonsmokers (Appendices D. 6
to D.7), from same patients with different regions, endometrium and cervix (Appendices D. 8 to
D.9). The master data table as modified is given in Appendix: G.1. According to this two way
analysis, there is no significant difference between endometrium and cervix in smokers in either
for CYP3A3/A4 or CYP3A7 enzymes, whereas, there is a significant difference between
endometrium and cervix in both isozymes among nonsmokers. Between the two regions,
endometrium and cervix among smokers, there is significant difference in expression of
CYP3A7 over CYP3A3/A4 and similar significance was observed in nonsmokers in cervix
region where CYP3A3/A4 is more than CYP3A7.

49

FIGURES

Figure: 5.1 Expression of CYP1A1 mRNA in Nonsmokers in three regions of
uterus
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Figure: 5.2 Expression of CYP1B1 mRNA in Nonsmokers in three regions of
uterus
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Figure 5.3: CYP1A1 and CYP1B1 expression in uterus
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Figure: 5.4 Expression of CYP1A1 mRNA in Smokers in three regions of
uterus
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Figure: 5.5 Expression of CYP1B1 mRNA in Smokers in three regions of
uterus
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Figure: 5.6 Expression of CYP1A1 and CYP1B1 in Endometrium –
comparison between nonsmokers and smokers
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Figure: 5.7 Expression of CYP 1A1 and CYP 1B1 in CERVIX –

comparison between nonsmokers and smokers
Figure5.7
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Fig: 5.8 Expression of CYP 1A1 and CYP 1B1 in SQUAMOUS
REGION - comparison between nonsmokers and smokers
Figure5.8
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Figure: 5.9 Ratio of CYP1A1/β
β-actin mRNA levels among nonsmokers and
smokers
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Figure: 5.10 Ratio of CYP1A1/β
β-actin mRNA levels among proliferative and
secretory phases
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Figure: 5.11 Ratio of CYP1B1/β
β-actin mRNA levels among nonsmokers and
smokers
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Figure: 5.12 Ratio of CYP1B1/β
β-actin mRNA levels among proliferative and
secretory phases
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Figure: 5.13 CYP3A Expression in ENDOMETRIUM with PROBES
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Figure: 5.14
CYP3A3/4 and CYP3A7 Expression in ENDOMETRIUM
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Figure: 5.15 CYP3A3/A4 AND CYP3A7 Expression in CERVIX
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Figure: 5.16 Expression of CYP3A3/4 and CYP3A7 - PROLIFERATIVE
ENDOMETRIUM
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Figure: 5.17 Expression of CYP3A3/4 AND CYP3A7 SECRETORY
ENDOMETRIUM
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CYP3A expression in ENDOMETRIUM

Fig: 5.18

Figure: 5.18 CYP3A expression in ENDOMETRIUM
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CYP 3A levels in CERVIX

Fig: 5.19

Figure: 5.19 CYP3A levels in CERVIX
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Figure : 5.20 Levels of CYP3A3/A4 by nonsmokers and smokers in
ENDOMETRIUM
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Figure: 5.21 Levels of CYP3A7 by nonsmokers and smokers in
ENDOMETRIUM
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Figure: 5.21b Levels of CYP3A7 levels in PROL and SECR
ENDOMETRIUM in nonsmokers and smokers
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Figure: 5.22 Levels of CYP3A3/A4 by nonsmokers and smokers in cervix
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Figure: 5.23 Levels of CYP3A7 by nonsmokers and smokers in cervix
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Note: E17, E18, E19, E20, E21 are smokers
E22, E23, E24, E25, E26 are nonsmokers

Figure: 5.24 Expression of CYP3A3/4 AND CYP3A7 in ENDOMETRIUM in
nonsmokers and smokers
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Note: C33, C34, C35, C36, C37 are smokers
C38, C39, C40, C41, C42 are nonsmokers.

Figure: 5.25 Expression of CYP3A3/4 AND CYP3A7 in CERVIX
in nonsmokers and smokers
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TABLES

Table 1

Table:1 Demographics of Patients
Pt ID
#
1

WT

AGE

SM/NS

COMEDICATION

DIAGNOSIS
FIBROID UTERUS
FOCAL MILD
CHRONIC
CERVICITIS AND
SQUAMOUS
METAPLASIA
SYMPTOMATIC
PELVIC
RELAXATION
FIBROID UTERUS,
SQUAMOUS
METAPLASIA OF
ENDOCERVIX
DYSMENORRHEA
,DYSPLASIAAND
ENDOMETRIOSIS
FIBROID UTERUS,
CHRONIC CYSTIC
CERVICITIS, and
ENDOCERVICAL
SQUAMOUS
METAPLASIA
CHRONIC PELVIC
PAIN,
LEIOMYOMAS,
MULTIPLE
FOLLICLE CYSTS

154

48

NS

SINEGUAM, DIAZIDE

2

277

38

NS

SYNTHROID,
PROLISEC

3

135

44

NS

DEMORAL,
PHENORGAN,
VALIUM

4

202.5

41

NS

KEFZOL, PROVRA,
VIBROMYCIN

5

142

48

NS

DRIXORAL, ATIVAN,
BC PILLS

6

186.1

37

NS

IMITREX, ANAPROX,
LODINE
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TABLE: 2 Demographics of all Patients analyzed for CYP1A1 and CYP1B1
during various stages of menstrual cycle and smoking status
PT
#

STAGE

WT

AGE

SM/NS

COMEDICATION

1 prol

154

48 ns

2 secr

277

38 ns

3 secr

202.5

41 ns

4 prol

135

44 ns

sineguam,
diazide
synthroid,
prolisec
kefzol, provra,
vibromycin
demoral,
phenorgan,
valium

5 prol

142

48 ns

drixoral, ativan,
bc pills

6 prol

186.1
2

37 ns

7 prol

230

38 sm

8 prol

165

29 sm

9 secr

124

41 sm

prozac
hydrochloro
thiazide

10 prol

112

25 sm

augmentin

11 secr

205

38 sm

morphine

imitrex,
anaprox, lodine
diet pills,
morphine
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DIAGNOSIS

Fibroid uterus focal
mild chronic cervicitis
and squamous
metaplasia
Symptomatic pelvic
relaxation
Dysmenorrhea,dysplasi
aand endometriosis
Fibroid uterus,
squamous metaplasia
of endocervix
Fibroid uterus, Chronic
cystic cervicitis, and
endocervical squamous
metaplasia
Chronic pelvic pain,
leiomyomas, multiple
follicle cysts
Menorrahagia,
enlarged uterus
Severe endometriosis,
pelvic pain,
dysporunia,
menorrhagia,
dysmenorrhea
Fibroid uterus,
Menorrhagia
Pelvic pain with
endometriosis
Fibroid uterus,
dysfunctional uterine
bleeding,
dysmenorrhea
Contd..
2

12 secr

195

35 ns

progestrone.

13 secr

266

56 ns

no

14 secr

215

49 ns

provra

15 secr

120

78 ns

morphine

16 secr

132

47 ns

provra

17 secr
18 prol
19 atrophic

181
148
200

48 sm
38 sm
62 sm

20 prol

186

39 sm

21 hyperplasia

213

41 sm

sudafed,
ibuprofen
no
ultram
progestrone,
aegestin, drug
sensitivity for
provra
depo-provra,
tolazamide

22 prol

112

37 sm

no
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Contd..
Vaginal bleeding,
Endometrial atrophy on
progestrone use, Endo
hyperplasia, Chronic
cervicitis, Nabothian cysts
of cervix, Focal
parakeratosis of exocervical
epithelium
Endometrial cancer,
rectocele, genuine stress,
urinary incontinence, post
menopausal bleeding
Uterine discensus,
cystocele,
rectocele,endometrial
hyperplasia, with atypia,
cervix showing nabothian
cysts and focal chronic
inflammaton.
Uterine diseensus,
cystocele, rectocele, fibroid
uterus
fibroid dysfunctional
uterus,endometrial
hyperplasia
Heavy pain ful periods,
pelvic relaxation, urinary
incontinence
Pelvic pain, endometriosis
Severe Cervical dysplasia
Pelvic endometriosis,
persistent pelvic pain, and
tenderness, possible
adenomyosis, menorrhagia.
Intractable uterine bleeding
Stage I and A-2 squamous
carcinoma of cervix

Table3

Table: 3 CYP1A1 expression levels in various regions as ratio with
β − actin

PT id #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Squamous Endometr

0.12595
3.96598
3.35676
4.46956
3.0548
1.75032
9.23558
1.8216
15.7428
1.10473
13.5322
0
1.13222
0.68485
1.64991
2.22665
0.7496
0.17768
0.90688
0.1738
0.48839
0.37408

0.40555
0.74032
2.12341
0.54298
3.02123
2.17854
2.96866
6.8105
8.73288
0
2.25665
12.3142
1.16218
0.05979
0.79901
1.49169
0.63925
0
0.18558
0.87274
1.2258
0.81056

Cervix

0
0
1.13086
0.19036
0
0.96513
0
1.84731
16.561
0
0.74667
13.6697
0.86855
1.18839
1.47769
0.27886
0.02866
0.10993
0.33963
0.19131
0.09724
0.15431

SM/NS
NS

STAGE
PROL

NS

SECR

NS

SECR

NS

PROL

NS

PROL

NS

PROL

SM
SM

SECR
PROL

SM

ATROPHIC

SM

HYPERPLASIA

SM

PROL

SM

PROL

SM

PROL

SM

PROL

SM

SECR

SM

PROL

SM

SECR

NS

SECR

NS

SECR

NS

SECR

NS

SECR

NS

SECR

PROL: Proliferative stage
SECR: Secretory stage
SM: Smokers
NS: Nonsmokers
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Table4

Table: 4

PT id #
1
2
3
4
5
6
7
8
9
10
11

CYP1B1 expression levels in various regions as ratio with
β−actin
β−
Squamous Endometrium

0
0
2.08222
0
0
3.19936
0
0
0
0
0

12
13
14
15
16
17
18
19
20
21
22

0
0
0
0
0.06335
0
0.08079
0
0
0

2.48632
0.07734
2.15973
2.84938
7.03089
3.07206
1.55331
1.51628
0.91298
0
4.53018
0
0
0.03325
0
0.05333
0.03706
0.02099
0
0.04947
0
0.53777

Cervix

0.26048
1.72426
0
0
0.27266
0
0
1.86394
0.365
0
0.32087
0.07821
0
0
0
0
0.27864
0.12023
0
0
0.05757

PROL: Proliferative
SECR: Secretory
SM: Smokers
NS: Nonsmokers
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SM/NS
NS

STAGE
PROL

NS

SECR

NS

SECR

NS

PROL

NS

PROL

NS

PROL

SM

SECR

SM

PROL

SM

ATROPHIC

SM

HYPERPLASIA

SM

PROL

SM

PROL

SM

PROL

SM

PROL

SM

SECR

SM

PROL

SM

SECR

NS

SECR

NS

SECR

NS

SECR

NS
NS

SECR
SECR

Table: 5

Demographics of patients used for CYP3A expression

Endo
#
E31

Cerv
#
C51

Stage

wt

inactive

217

E32

C52

secr

E33

C53

E34

Age

SM/NS

Comedication

diagnosis

49 NS

Prednisone

148

36 SM*

Naproxin

prol

237

34 NS

Glucotrol,
Lotrel,
Percocet,
Colace

C54

prol/ca

225

46 NS

Synthroid,
Provera,
Pravachol

E35

C56

secr

120

35 NS

Nil

E36

C57

secr

185

38 SM

Nil

E37

C58

secr

119

41 NS

Naprosyn

E38

C59

prol

105

42 NS

E39

C60

inactive

140

74 NS

Droperidol,kef
zol, Cefazolin
Synthroid,
Cipro, Asprin,
vit e, captocil

Pelvic
pain,
Prolapse
Chronic
pelvic
pain
Recurrent
uterine
bleeding,
Persistent
complex
hyperplas
ia
Fibroid
uterus,
Bleeding,
Polyps
Pelvic
lymphede
ctomy,
Cervical
cancer?
Fibroid
uterus,
multiple
myomas
Pelvic
pain,
Pelvic
mass
Fibroid
uterus
Pelvic
pain
Contd..
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Contd..
E40

C61

prol

270

47 SM**

Cipro

E41

C62

secr

134

31 NS

Serzone,
Trazodone,
Ventolin
inhaler,
Proventil,
prednisone etc.

E42

C63

prol

149

44 NS

E43

C64

secr

168

40 SM

Premarin,
colace, tylenol
Anaprox,
lorezapam,
pyroxicam

*only one patient is black.
** One patient is smoker for 12 years but quit smoking in 1973
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Hernia,
menomet
rorrhagea
Fibroid
uterus,
ovarian
cysts,
chronic
pelvic
pain
Uterine
fibroids
Endometr
iosis

Table: 6

ID#
E1
E4
E5
E7
E8
E9
E10
E13
E16
E17
E18
E20
E11
E14
E15
E19
E21
E23
E24
E25
E26
E22
E31
E32
E33
E34
E35
E36
E37
E38
E39
E40
E41
E42
E43

Levels of CYP3A3/A4 and CYP3A7 as ratios with
respective β actin levels
STAGE SM / NS
PROL
SM
PROL
NS
PROL
SM
PROL
NS
PROL
NS
PROL
NS
PROL
SM
PROL
NS
PROL
NS
PROL
SM
PROL
SM
PROL
SM
SECR
NS
SECR
NS
SECR
SM
SECR
SM
SECR
SM
SECR
NS
SECR
NS
SECR
NS
SECR
NS
SECR
NS
INACTIVE
NS
SECR
SM*
PROL
NS
PROL/CA
NS
SECR
NS
SECR
SM
SECR
NS
PROL
NS
INACTIVE
NS
PROL
SM**
SECR
NS
PROL
NS
SECR
SM

3A3 /A4
0
0
950517
2152962
0
3128568
4619279
8971099
0
6976845
0
7769961
4243992
2403039
26821
432695
42844
6938609
8473469
4252467
5853757
0
16144.86
5188.64
56258.25
22997.22
5060.3
109528.2
374089.3
33689.78
53867.4
96553.12
274711.9
68775.67
279421.2

3A7
0
0
14223601
91058
0
10664064
9430575
2659004
127022
19244217
0
5457450
95210
10567
390583
154682
34066
81577
114550
1146260
1053534
904271
593082
59660.02
1014889
1032549
61469.89
899699.7
295883.6
256547.4
1521953
428051.7
574076.6
29237.53
101713.1
Contd…
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Contd..

3A3/3A4 and 3A7 DATA ON CERVIX
3A3/3A4
C33
PROL
SM
0
C34
PROL
SM
18427
C35
SECR
SM
0
C36
PROL
SM
12748
C37
SECR
SM
30978
C38
SECR
NS
15755
C39
SECR
NS
0
C40
SECR
NS
0
C41
SECR
NS
0
C42
SECR
NS
0
C51
INACTIVE
NS
8260.72
C52
SECR
SM*
0
C53
PROL
NS
1754.84
C54
PROL/CA
NS
0
C56
SECR
NS
1411.7
C57
SECR
SM
3002.82
C58
SECR
NS
0
C59
PROL
NS
0
C60
INACTIVE
NS
2636.4
C61
PROL
SM**
1422.36
C62
SECR
NS
29144.06
C63
PROL
NS
2312.09
C64
SECR
SM
1941.52

3A7
0
533427
0
59205
615701
1522111
922991
0
1111309
0
619157.8
35017.32
18999.14
9095.2
10089.04
19757.01
-205.07
536.31
14631.52
8284.52
9226.17
14586.55
7218.67

* This is the only case who is black.
**Smoker for 12 years but quit smoking in 1973.
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DISCUSSION
The CYP1A1 and CYP1B1 isoforms are key enzymes in the formation of reactive
metabolites from procarcinogens (Juchau et al.1982; Kawajiri et al. 1991; Kociba et al. 1978)
and therefore play an important role in determining the carcinogenic outcome. Variability in the
expression of these enzymes in barrier extrahepatic tissues e.g. lung (Liehr et al. 1986) may
provide an explanation for differential susceptibility to neoplasia in some individuals. To date,
no reports exist regarding evaluation of the constituent expression of CYP1A1 and CYP1B1 in
human uterine tissue. While CYP1A1 is generally believed to be predominantly an extrahepatic
enzyme (Liehr et al. 1996), CYP1B1 is also expressed constitutively in extrahepatic organs such
as breast, prostate and lung (Liehr et al. 1995). Moreover, recent findings suggest that CYP1B1
is a key enzyme in estradiol hydroxylation (Hayes et al. 1996). The catechol estrogens lead to
inactivation of estrogenic activity, however, they are toxicologically active and appear to play a
role in toxicity and tumorigenesis (Liehr et al. 1990; Lucier et al. 1991). The mechanism for
these toxic effects appears to involve free radicals, generated from the reductive-oxidative
cycling of the catechol estrogens with their corresponding semiquinone and quinone forms,
which cause cellular damage (McManus et al. 1990; Nutter et al. 1994; Shimada, et al. 1989).
Therefore, alterations in the expression of these two isoforms may help us better understand the
role of procarcinogen activation in human tumors of extrahepatic origin.
In our study we have shown that CYP1A1 and CYP1B1 are constitutively expressed in
the endometrial tissue of the human uterus which does not seem to vary significantly in
nonsmoking women without malignant indications. Although we observed a significantly lower
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expression of CYP1B1 in a patient with secretory endometrium, further investigation is indicated
to determine if the menstrual phase could account for this observation. It can be speculated that
the variations in hormonal levels during the menstrual cycle may impact the expression of
CYP1B1, particularly in regard to the endocrine regulatory role of this enzyme. Interestingly,
even though CYP1A1 is predominantly an extrahepatic enzyme, expression of this isoform was
minimal in the cervix and squamous region (except for patient #3). Probably due to proliferative
nature of the endometrial glands and the sensitive responsiveness of this tissue to hormonal
influences, the CYP1 family isoforms are constitutively expressed in the endometrium.
Metabolism of estrogens is primarily hepatic, nevertheless some metabolism has been observed
in physiologically relevant extrahepatic tissues e.g. breast (Shimada et al. 1992), uterus (Hakkola
et al. 1996) and placenta (Sutter et al. 1994). It is likely that the constitutive expression of
CYP1A1 and CYP1B1 in human endometrium plays a critical role in the localized metabolism
of estrogens. Differential expression of these isoforms may have an impact on the extent of
localized inactivation of the estrogens and hence may determine the physiologic and toxicologic
outcome.
The study included 22 patients in whom expression of CYP1A1 and CYP1B1 in three
different regions with respect to smoking and nonsmoking status and also different stages of
menstrual cycle have been considered. In particular, mRNA encoding for CYP1B1 was
completely absent from the squamous (exocervix) region and was not expressed in cervix of
more than half of the patients. Moreover, significant expression of CYP1B1 was observed in the
endometrium, which appeared to vary with the menstrual phase. Transcripts coding for CYP1A1
appeared to be significantly induced in the cervix of smokers compared to nonsmokers, but
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differences in phases of menstrual cycle had no apparent effect on the expression of that
isozyme. Such variable expression of CYP1A1 and CYP1B1, in different regions of the uterus of
smokers and nonsmokers, could explain the differential susceptibility of smokers and
nonsmokers to cervical and endometrial cancer.
Variability in the expression of these enzymes in barrier and extrahepatic tissues such as
lung (Shimada et al. 1992) and uterus may provide an explanation for differential susceptibility
to neoplasia in some individuals. Similar to CYP1A1, which is generally believed to be
predominantly an extrahepatic enzyme (Masters et al. 1987), CYP1B1 is also expressed
constitutively in extrahepatic tissues such as breast, prostate and lung (Brake et al. 1995). These
data confirm a recent report of CYP1B1 expression in endometrium (Murray et al. 1997).
Moreover, recent findings suggest that CYP1B1 is a key enzyme in estradiol hydroxylation
(Hayes et al. 1996). Catechol estrogens lead to inactivation of estrogenic activity, however, they
are toxicologically active and appear to play a role in tumorigenesis (Ikawa et al. 1995; Murray
et.al.1997). The mechanism by which these toxic effects occur involves formation of free
radicals, generated by the reductive-oxidative cycling of the catechol estrogens with their
corresponding semiquinone and quinone forms, causing cellular damage (Liehr et al. 1990,
Dwivedy et al. 1992; Nutter et. al 1994). Therefore, while CYP1A1 is a key enzyme involved in
activation of procarcinogens from cigarette smoke and other environmental pollutants, CYP1B1
plays an equally important role in promoting estrogen induced cancers.
The patient demographic data (Tables 1, 2 and 3) do not indicate prolonged enzyme
releasing therapy. However, some individual response for specific CYP enzymes can not be
ruled out. That kind of analysis is outside the purview of this study. So, based on the overview
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of medication, length of use of drugs and disease conditions, it is reasonable to assume that
expression of CYPs is modulated by factors other than drugs and disease of the patients.
The CYP1A1 mRNA is significantly induced in smokers whereas the CYP1B1 mRNA
appears to be down regulated. Although, each isoform is thought to be induced via the nuclear
ligand/Ah receptor complexes, mediated atypical induction (Eugster et al. 1993; Nebert et al.
1994), profiles for these isoforms have been observed in other extrahepatic tissues. For example,
in the glomerular mesangial cell (Bowes et al.1996) as well as the liver, lung and thymus (Vogel
et al. 1997), TCDD induces CYP1B1 more effectively than CYP1A1. Whereas the pattern of
induction is reversed with benzo(a)pyrene (Bowes et al. 1996), CYP1A1 is induced
predominantly, without much effect on CYP1B1. It seems likely that such a differential
induction of CYP1A1 and CYP1B1 mRNA is occurring in the uterine tissue of smokers. Not
only are there differences between the two isoforms, but regiospecific induction of CYP1A1
occurs in the uterus. A 12-fold increase in CYP1A1 mRNA was seen in the cervix, whereas only
a 2-fold induction of CYP1A1 mRNA was observed in the endometrium and squamous
(exocervix) region. It is well established that PAHs influence the accumulation of the CYP1A
mRNAs by both transcriptional and post-transcriptional mechanisms (Pasco et al. 1988). It has
also been shown that induction of CYP1A mRNA is followed by a proportional increase in
catalytic activity (Pasanen et al. 1988). Since CYP1A1 is the key enzyme involved in the
conversion of benzo(a)pyrene to highly reactive epoxides (Miller et.al. 1990), increased enzyme
levels would generate greater amounts of reactive metabolites. This increased CYP1A1 activity
and expression might explain the increased risk of cervical cancer in some smokers. Further
evidence of carcinogenicity of PAHs from cigarette smoke in the cervix is provided by the
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appearance of elevated levels of DNA adducts in cervical epithelium (Otsuki et al.1994).
Interestingly, the patient previously treated for CIN III had no detectable CYP1A1 mRNA,
probably because the atypical tissue at the squamous-columnar epithelial junction had been
completely removed during the previous surgical procedure.
A significantly lower expression of CYP1B1 (p<0.05) in patients with secretory
endometrium and absence of detectable mRNA in the postmenopausal women (patients # 15 and
#19) suggest that CYP1B1 regulation is altered during the menstrual cycle. The endometrium
responds to ovarian steroid hormones in a series of clearly distinct phases which characterize the
menstrual cycle. Estrogen dependent proliferation and progesterone dependent differentiation of
the endometrium are well documented. Cyclic expression of other genes during the menstrual
cycle has been previously reported (Loza et al. 1991). It can be speculated that hormonal
variation during the menstrual cycle may have some impact on the expression of CYP1B1,
particularly due to the endocrine regulatory role of this enzyme. It is possible that the
constitutive expression of CYP1A1 and CYP1B1 in the human endometrium plays a critical role
in the localized metabolism of estrogens. This is particularly relevant since some estrogen
metabolism has been observed in the uterus (Sholl et. al 1983; Rock et al. 1994). The
significance of variation in expression of CYP1B1 in the menstrual cycle is borne out by the
observation that endometrial cancer most commonly occurs in women who do not ovulate
regularly. Such cases commonly show a persistence of proliferative endometrium along with
absence of secretory endometrium. Based on our results, it can be speculated that in some
women a differential expression of the CYP1B1 isoforms may exist, thereby increasing
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susceptibility to exposure from catechol estrogens resulting from localized estrogen metabolism
in the endometrium.
It has been demonstrated that human endometrium, as well as cervix from women
undergoing hysterectomy for benign conditions, express CYP3A4 and CYP3A7. This
observation supports the previous finding of CYP3A7 mRNA in endometrium from 5 pregnant
women (Schuetz et al. 1993). The appearance of the CYP3A isoform was documented by
RT-PCR, and southern blot hybridization techniques. Based on the results, it appears that human
cervix minimally expresses CYP3A isoforms, however significant expression is seen in the
endometrium that is highly variable, possibly due to cyclic expression. Particularly, the
CYP3A7 mRNA appeared to be much higher in the proliferative phase compared to the secretory
phase. The expression of CYP3A4 and CYP3A7 mRNA in human endometrium suggests that it
might be an important site for intermediary steroid metabolism. The CYP3A family is known to
be inducible, for example the CYP3A mRNA increases in response to the administration of
synthetic and natural glucocorticoids (Molowa et al. 1986; Scheutz et al. 1984), macrolide
antiobiotics (Watkins et al. 1986), rifampin and rifabutin (Oesch et al. 1996), environmental
agents such as polychlorinated biphenyls (PCBs) and organochlorine pesticides (Scheutz et al.
1986). We observed an increase in the CYP3A7 mRNA in endometrium associated with the
menstrual phase. The possibility of enzyme induction cannot be ruled out, particularly by
exposure to PCBs, dichlorodiphenyltrichlorethane and other persistent lipophilic environmental
agents that are virtually ubiquitous in the general US population (Stehr-Green et al. 1986).
However, the increase in CYP3A7 mRNA occurred consistently in the proliferative phase in
most patients, suggesting that the changes in the amounts of endogenous substrates and
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hormones can affect CYP3A expression in the endometrium. The reported 3 to 4-fold increase in
endometrial tissue concentrations of DHEA-s, a known substrate for CYP3A7 (Kitada et.al.
1987), during the secretory phase in premenopausal women (Bonney et al. 1984) coincides with
the decreased levels of CYP3A7 seen in our study. Transcription for the rat liver CYP3A
isoform, CYP3A1, is controlled by a nonclassical glucocorticoid receptor mediated process
(Burger et al. 1992.). Moreover, the synthetic glucocorticoid agonist, dexamethasone, induces
CYP3A7 mRNA in the human hepatoblastoma HEPG2 (Beach et al. 1992) through
transcriptional activation of CYP3A7. These observations suggest that steroid hormones and
their receptors play a role in the regulation of CYP3A7. The 11 beta-hydroxysteroid
dehyrogenase type II enzyme, a potent inactivator of glucocorticoids, is significantly lower
during the proliferative phase compared to the secretory phase of the menstrual cycle (Smith
et.al.1997), probably resulting in higher tissue levels of glucocorticoids. Moreover, the
endometrial mRNA levels of coritocosteroid binding globulin (CBG) which binds steroid
hormones and plays a role in their transportation, were significantly higher in the secretory phase
compared to the proliferative phase (Misao et.al. 1994). These findings suggest that high tissue
specific levels of CBG, in the endometrium would result in increased binding of glucocorticoids
thereby reducing the exposure of endometrium to free glucocorticoids. This decreased tissue
specific exposure to glucocorticoids might account for the relative downregulation of CYP3A7
in secretory phase, since this isoform is susceptible to glucocorticoid induction. Further
investigations are necessary to clearly elucidate whether the increased mRNA levels of CYP3A7
in the proliferative phase are due to upregulation, or lower mRNA levels in the secretory phase
are due to downregulation.
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Panel: A

3A3/A4
E
C

SM

NS

not significant

significant
(E>C)

Panel: B
ENDO
3A3---3A7

CERV
3A3---3A7

SM

significant
(3A3<3A7)

not significant

NS

not significant

3A7
E
C

not significant

Significant
(E>C)

Significant
(3A3<3A7)

Figure: 6.1. The comparative analysis of CYP3A expressions in endometrium and cervix

Both enzymes CYP3A3/A4 and CYP3A7 have exhibited a possible interdependent
relationship in their induction in uterine tissue in smokers and nonsmokers. Only nonsmokers
exhibited significant expression of these enzymes in endometrium, which is due to higher
estrogen stimulus present in this tissue. Further, the endometrial tissue is in a state of continuous
growth and DNA also is in continuous and regular replication, which explains the enhanced
induction and expression of their mRNA. Whereas in smokers, absence of this phenomenon
explains that constitutive presence of smoking related procarcinogens alter the induction levels
of these CYPs in the both regions of cervix and endometrium. Inactivation of procarcinogens
like BP is catalyzed by these CYPs, which are also involved in estrogen metabolism. Therefore
levels of CYP3A7 and CYP3A3/A4 enzymes were elevated among smokers (Figure 6.1-A). The
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differential expression of these two isozymes in the same tissue within the group of smokers and
nonsmokers reveals similar findings and agrees with the hypothesis of CYP mediated BP
catalysis in uterine tissue. The smokers exhibited elevated levels of CYP3A3/A4 more than
CYP3A7 in endometrium. Similar significance was evident in nonsmokers in cervix region.
This explains the relative importance of CYP3A3/A4. BP induces CYP3A3/A4, which
participates in estrogen metabolism. Thus, there is the least chance of overexposure of estrogen
in endometrial tissues among smokers. This explains the phenomenon of smokers exhibiting
reduced incidence of endometrial cancer. In nonsmokers CYP3A7 is significantly higher in
cervix which possibly offers protective mechanism against estrogen exposure (Figure 6.1-B).
Both of these enzymes have shown a balanced expression in nonsmokers endometrium and
smokers cervix. The absence of statistical significance may not disprove the relative roles of
these enzymes, however the differences in the expression of both isoforms could be clinically
significant. The location of enhanced activity for CYP3A7 in cervix seemed to translocate to
endometrium region among smokers possibly due to some intracellular mechanism or through
higher levels of BP like procarcinogens present in cigarette smoking.
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CONCLUSIONS
1. Evaluation of cytochrome P450 expression in uterine tissue revealed that CYP1A1 CYP1B1
and CYP3A3/A4 and CYP3A7 isoforms are constitutively expressed in endometrium,
endocervix and squamous (exocervix) regions. The expression levels are variable in the tissues
depending on the cyclic changes and nature of the tissue, which are also dependent on other
metabolic stimulii.
2. Smoking induced the expression of CYP1A1, CYP3A3/A4 and CYP3A7 in differential
manner depending on the stages of endometrium.
3. Differential expression of these isoforms was indicative of CYP involvement in smoking
related carcinogenesis.
4. Expression of CYP1B1 was significantly higher in endometrium and extremely low in
secretory stage of menstrual phase whereas expression of CYP1A1 was significantly higher in
squamous region. A 20-fold increase in CYP1B1 was observed in endometrium of proliferative
phase. CYP1B1 was expressed in only 2 out of 6 patients in squamous (exocervix) region, and 3
out of 5 patients in cervix. CYP1A1 was expressed in the endometrium of all except one patient.
No difference for CYP1A1 mRNA expression could be observed in the three regions when
compared to proliferative or secretory phases of menstrual cycle
5. CYP1B1 expression appeared to be lower in smokers by 3-fold and no measurable expression
was seen in squamous (exocervix) region. A 12-fold increase in expression of CYP1A1 was
evident in cervix of smokers compared to nonsmokers.
6. CYP3A isoforms are expressed in human endometrium. Cyclic variability of CYP3A3/4 and
CYP3A7 during the proliferative and secretory phase might be due to the variations in hormonal
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levels in the uterus. Differential expression of the CYP3A isoforms suggests possible
physiological function of these enzymes in the uterus.
7. Differential expression of CYP3A isoforms in the menstrual phase between smokers and
nonsmokers suggests that these enzymes might play a role in the toxicological outcome in the
uterus. No difference in expression of CYP3A3/3A4 was observed in different stages of
endometrium.
8. Significant decrease of CYP3A3/3A4 was observed among smokers by 30-fold than
nonsmokers in secretory phase. Expression of CYP3A7 increased 17-fold in proliferative stage
than in secretory phase in endometrium.
9. A 40-fold and 20-fold higher expression, respectively of CYP3A7 and CYP3A3/3A4 were
observed in proliferative and secretory phases in smokers.
10. No significant difference was noticed for either of isoforms in different menstrual phases
among overall comparison of smokers and nonsmokers.
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FUTURE RESEARCH DIRECTIONS
The identifiction of cytochromes and their characterization significantly improves our
understanding of drug metabolism. The related genotoxic studies help to identify the
susceptability to various xenobiotics in different individuals. However, investigations should be
aimed at the identification of cytochrome P450s in a non-invasive, rapid and accurate manner
sothat, bench mark susceptibility levels could be determined. Genetic predisposition studies
could be directed to the detection of active cytochrome gene expression and to use them as
biomarkers.
CYP genes appear to be primarily regulated at the transcriptional level. Some reports
implicate post transcriptional and post translational regulation in rabbits (Costas 1996). It would
seem therefore, the post translational investigation of CYP3A will give more information on how
CYP3A is able to contribute to carcinogenesis.
Possible small nuclear proteins associated with cytochromes may be implicated in
activating the CYP enzymes which could be investigated or identified to substantiate the signal
transduction process of bulky DNA adduct formation. The targetting of drugs could be
investigated with respect to their ability to induce various CYPs.
Following populations could be studied to gain additional insight on cancer.
a) Populations suffering with cancer due to environmental estrogens or potentially
exposed to PAH in smoke or cigarette smoking.
b) Populations, those are demographically matched with smoking and nonsmoking status
but are not suffering from cancer.
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The expression levels of cytochrome P450s relating to various races or geographic
localization would throw light on susceptibility to carcinogenicity due to CYP inductions in
those populations. Further studies to assess the high risk populations of uterine cancer by
measuring genetic expressions of CYP enzymes and the associated polymorphisms will help in
addressing the preventive and environmental scanning measures.
Mutation in DNA repair proteins, which are likely to contribute to excessive proliferation
of endometrial tissue can be investigated. This would validate that proliferation alone is the
contributory engine for carcinogenesis. Some of the oncogene activation and disturbance in
apoptotic response due to CYP activation could be studied in uterine cancer where investigations
on tumor suppressor genes and oncogenes in uterine cancer are likely to be the future areas of
interest. It is also possible that other CYP families may be involved in endometrial and cervical
cancer development, which can be investigated further. CYP activation is of major interest to
drug industry for its role in predicting cytotoxicity. It still needs to be confirmed that CYP
induction is the predisposing factor.
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APPENDICES

Appendix: A

Quality of mRNA from three tissues of uterus
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Appendix: B

β−Actin
expression in three regions of uterus
β−

cervix

2000
1500
1000
700
500
400

890 bp

bp
bp
bp
bp
bp
bp

pt# 1 4 3 5 6 MW Marker

1500
1000
700
500
400

endometrium

bp
bp
bp
bp
bp

pt# 1 2 3 4 5 6 MW Marker

1500 bp
1000 bp
700 bp

squamous region

500 bp
400 bp

pt# Ctrl 1 2 4 3 5 6 MW Marker

123

Appendix: C

Titration Analysis
mRNA of ENDO (E7) and (E11) were taken as representative samples to express CYP1B1 and
CYP1A1 for titration study.
Serial dilution was done as follows and PCR amplification was done with similar conditions for
30 cycles and quantification was estimated with densitometric analysis.
Lane 1: 2ml of cDNA of E11.
Lane 2: 2ml of (2ml of cDNA + 2 ml DEPC water)
Lane 3: 2ml of (2ml of item #2 + 2ml DEPC water)
Lane 4: 2ml of (2ml of item # 3 + 2ml DEPC water)
Lanes 5 to 8 as above with E7
Lane 9: +ve control

Lanes:

9

8

7

6

5

4

3

2

1

490 bp

146 bp (CYP1A1)

+ve

E7 E7

E7

E7

E11 E11 E11 E11 MW
Marker
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Appendix: D.

Materials and Equipment
Chloroform (ACS grade)
Isopropanol (ACS grade)
Ethanol (ACS grade)
RNA stat-60 (100ml or 200 ml bottle containing a red solution of RNA stat-60 which contains
phenol and guanidinium thiocyanate in a monophase solution) obtained from TEL-TEST “B”,
inc., PO BOX 1421, 1511 County road 129, Friendswood, TX 77546. 1-800-631-0600.)
Liquid nitrogen
Primers designed using oligo and dnasis software and obtained from Gibco-BRL, Gaithersburg,
MD, USA.
Reverse Transcription reaction Buffer – Gibco-BRL
M-MLV Reverse Transcriptase - Gibco-BRL
10mM Dithiothreitol (DTT)- Gibco-BRL
Oligo (dT)- Gibco-BRL
DNTP- Gibco-BRL
25mM Magnesium chloride- Gibco-BRL
Taq polymerase - Promega Corporation
Primers for

-Actin - Clonetech, Palo Alto, CA, USA

Control RNA (891-bp CAT derived)- Clonetech, Palo Alto, CA, USA
DNA size markers – Bio-Rad,
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Agarose - FMC
BiS- Acrylamide (N,N’-methylene bisacrylamide )- Sigma
Ammonium per sulphate - Sigma
Temed - sigma
Tris Hydrochloride - Sigma
Qia quick purification kits - Qiagen
Qia quick gel extraction kits - Qiagen
10X SSC
α- 32P dCTP – radionucleotides ( Redivue Nucleotides) - Amersham pharmacia
0.1% Sodium Dodecyl Sulphate (SDS) -Sigma
Formamide - Sigma
Sodium phosphate (monobasic and dibasic salts) – Fisher Scientific
Sodium Chloride – Fisher Scientific
EthylenediaminetetraaceticAcid (EDTA) solutions - Sigma
Salmon Sperm DNA – Promega Corporation
Random prime kit- Gibco-BRL
5’- End labelling kit – Promega Corporation
Sodium Hydroxide solutions – Fisher Scientific
TBE buffer
Buffered phenol chloroform – Gibco-BRL
Ethidium bromide solution - Sigma
Di Ethyl Pyro carbonate (DEPC) - Sigma
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Formaldehyde – Fisher Scientific
Sodium Acetate – Fisher Scientific
MOPS – Sigma
Eppendorf tubes (centrifuge tubes)
Mortar and pessle
Perkin – Elmer Thermal cycler system 2400 and 480 – PE Biosystems.
Thin walled PCR Tubes- Fisher Scientific, Pittsburgh. PA, USA
Eagles eye software and hardware.
Optimas software,
Phosphor Imager,
Photo plates for Phosphor imager
Imagequant software
Zeta probe Nylon membranes - Bio-rad
G-50 sephadex columns - Boehringer Mannheim
UV Cross linker - Stratagene
Electrophoresis apparatus - Owl apparatus
Hybridization oven – Stovall.
Spectrphotometer – Beckman
Polypropylene tubes 13ml 17X75 mm – Molecular Research center, Inc.
-700C Freezer
Ultra centrifuge- Beckmann
Pipettors – Eppendorf
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Buffers Used:
1. Loading Buffer for RNA:
Formamide – 750 l
20X Mops – 75 l
Glycerol – 100 l
Formaldehyde – 240 l
0.5% DEPC water – 540 l
Bromophenol blue – a pinch (about 2.5%)
2. Formaldehyde Gel (for 14 well large cast)
Agarose – 50ml
Formaldehyde- 2.7ml
Ethydium bromide – 2.0 l
3.Running Buffer for Formaldehyde Gel
20X mops 30ml
Ethydium Bromide 20 l
Formaldehyde – 20ml
0.5% DEPC water QS – 600 ml
4. 10X SSC
3M Sodium chloride – 175 gm
0.3M Sodium Citrate – 88.2gm
Water q.s ----- 200 ml
Adjust PH to 7.0 with 1M HCl and make volume to 1 Litre.
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5. MOPS – 20X
0.4M MOPS PH 7.0
0.16M Sodium Acetate
0.02M EDTA PH 8.0
Adjust PH to 7.0 with 2N NaoH
sterile filter with 0.2mm millipore filter
6. 0.5% DEPC water
Add 5gm of DEPC in 5 litre of milliq water. Keep overnight, filter and autoclave and
store at 40C.
7. TBE buffer – 1 litre contains
100mM Tris
90mM Boric acid
1.0mM EDTA
Reference: Sambrook et al. 1989.
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Appendix: E

PATIENT INFORMATION (SMOKER / NONSMOKER)

Patients’s Name:

Hospital ID#:
Pathology ID#:

Age at the time of Surgery:

Date of Surgery:

Weight:
Race:
Address:

Telephone Number:

Pre-operative Diagnosis:

Name of Surgeon:

Occupation:
Number of cigarettes Smoked:

Number of Years smoking cigarettes

Do any members of the family smoke (indirect impact of smoking)
Alcohol consumption:
Comedication: (Not more than 1 year before surgery)

Medical History
Family History
130

AppendixF

Appendix: F
RNA concentrations from the tissues and their
identifications of all patients.
Tissues used for 1A1 and 1B1 expression

PT #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Endometrium Squamous
4.288
3.767
4.443
0.267
1.004
6.329
8.209
9.57
10.498
7.126
6.413
2.628
3.94
2.01
8.1
1.51
3.305
1.27
0.458
1.74
0.107
0.813

0.967
0.193
1.028
0.136
1.208
1.042
1.15
1.65
1.032
2.79
1.64
2.13
1.63
0.308
1.498
1.62
1.16
0.732
1.038
2.68
2.407
NA

Cervix
0.345
na
0.633
0.218
0.512
4.409
3.11
3.53
2.42
2.13
2.06
2.25
1.53
1.45
2.28
3.09
NA
3.779
0.364
1.388
1.966
0.344

Name
BM
BJ
WD
DS
VL
GJ
BG
WB
LS
PC
ED
VS
RN
BC
VD
CH
BC
BL
VM
HD
WD
BW

Tissues used for CYP 3A expression
Endo
Tissue
Id#
E31
E32
E33
E34
E35
E36
E37
E38
E39
E40
E41
E42
E43

Conc

3.247
3.982
4.995
6.161
3.46
2.878
2.74
3.913
3.9
3.175
7.241
3.159
3.228

Cerv ID #

C51
C52
C53
C54
C56
C57
C58
C59
C60
C61
C62
C63
C64

Conc

1.11
0.96
1.43
1.68
1.17
0.58
0.49
1.56
5.16
1.3
4.92
1.63
1.6

Name

KS
DD
HR
BG
LH
KC
BC
LF
YH
TD
MP
PK
MR
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Appendix: G.1

Master Data – Expression levels of CYP3A3/A4 and CYP3A7 as ratio to βActin and the relative differences

ID#
BW
RA
HS
GJ
VD
DS
DN
BL
BM
BG
WB
PC
WD
BJ
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LS
ED
RA
BC
VD
CH
KS
DD
HR
BG
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KC
BC
LF
YH
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stage
p
p
p
p
p
p
p
p
p
p
p
p
s
s
s
s
s
s
s
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s
a
s
p
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s
s
s
p
a
p
s
p
s
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0.
0.
0
0.
0.
0
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-1.3E+07
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91058 .
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0.
0.
0
3128568 .
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2659004 .
6312095
0.
127022 .
-127022
6976845 .
19244217 .
-1.2E+07
0.
0.
0
7769961
12748 5457450
59205 7757213 5398245 2312511
-46457
4243992
18427
95210 533427 4225565 -438217 4148782 -515000
2403039 .
10567 .
2392472
26821 .
390583 .
-363762
432695
0 154682
0 432695 154682 278013
0
42844
30978
34066 615701
11866 -581635
8778 -584723
6938609
0
81577 922991 6938609 -841414 6857032 -922991
8473469
0 114550
0 8473469 114550 8358919
0
4252467
0 1146260 1111309 4252467
34951 3106207 -1111309
5853757
0 1053534
0 5853757 1053534 4800223
0
16144.86 8260.72 593082 619157.8 7884.14 -26075.8 -576937 -610897
5188.64
-44.35 59660.02 35017.32 5232.99 24642.7 -54471.4 -35061.7
56258.25 1754.84 1014889 18999.14 54503.41 995890.1 -958631 -17244.3
22997.22
-4.95 1032549
9095.2 23002.17 1023453 -1009551 -9100.15
5060.3
1411.7 61469.89 10089.04
3648.6 51380.85 -56409.6 -8677.34
109528.2 3002.82 899699.7 19757.01 106525.4 879942.7 -790171 -16754.2
374089.3 -125.59 295883.6 -205.07 374214.9 296088.7 78205.68
79.48
33689.78 -467.82 256547.4
536.31 34157.6 256011.1 -222858 -1004.13
53867.4
2636.4 1521953 14631.52
51231 1507322 -1468086 -11995.1
96553.12 1422.36 428051.7 8284.52 95130.76 419767.2 -331499 -6862.16
274711.9 29144.06 574076.6 9226.17 245567.8 564850.4 -299365 19917.89
68775.67 2312.09 29237.53 14586.55 66463.58 14650.98 39538.14 -12274.5
279421.2 1941.52 101713.1 7218.67 277479.6 94494.42 177708.1 -5277.15
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Appendix: G.2
The expression of CYP3A3/A4 - Model with no interaction:
Response: 3A3/A4
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.168844
0.138061
2287082
1206368
57

Effect Test
Source
SM/NS
REGION

Nparm
1
1

DF
1
1

Sum of Squares
1.78821e12
5.54076e13

F Ratio
0.3419
10.5927

Prob>F
0.5612
0.0020

Mean Square
2.869e13
5.231e12

F Ratio
5.4849
Prob>F
0.0068

Whole-Model Test
Analysis of Variance
Source
Model
Error
C Total

DF
2
54
56

Sum of Squares
5.73801e13
2.8246e+14
3.3984e+14

SM/NS
Effect Test
Sum of Squares
1.78821e12

F Ratio
0.3419

DF
1

Prob>F
0.5612

Least Squares Means
Level
NS
SM

Least Sq Mean
1152879.963
789032.981

Std Error
391487.9228
490828.1523

Mean
1353852
971735

REGION
Effect Test
Sum of Squares
5.54076e13

F Ratio
10.5927

DF
1

Prob>F
0.0020

Least Squares Means
Level
C
E

Least Sq Mean
-33905.345
1975818.289
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Std Error
481662.5047
399005.1772

Mean
5643
2018624

Appendix: G.3
The expression of CYP3A3/A4 - Model with interaction:
Response: 3A3/A4
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.172498
0.125659
2303477
1206368
57

Effect Test
Source
SM/NS
REGION
SM/NS*REGION

Nparm
1
1
1

DF
1
1
1

Sum of Squares
1.21595e12
4.90422e13
1.24185e12

F Ratio
0.2292
9.2428
0.2340

Prob>F
0.6341
0.0037
0.6305

Whole-Model Test
Analysis of Variance
Source
Model
Error
C Total

DF
3
53
56

Sum of Squares
5.86219e13
2.81218e14
3.3984e+14

Mean Square
1.954e13
5.306e12

F Ratio
3.6827
Prob>F
0.0175

SM/NS
Effect Test
Sum of Squares
1.21595e12

F Ratio
0.2292

DF
1

Prob>F
0.6341

Least Squares Means
Level
NS
SM

Least Sq Mean
1128939.734
823408.694

Std Error
397387.4840
499427.2527

Mean
1353852
971735

REGION
Effect Test
Sum of Squares
4.90422e13

F Ratio
9.2428

DF
1

Prob>F
0.0037

Least Squares Means
Level
C
E

Least Sq Mean
5995.036
1946353.391
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Std Error
492076.3279
406454.5248

Mean
5643
2018624

SM/NS*REGION
Profile Plot
9000000
3A3/4 LSMeans

7000000
5000000
3000000

NS
SM

1000000

-1000000
C
E
REGION

Effect Test
Sum of Squares
1.24185e12

F Ratio
0.2340

DF
1

Prob>F
0.6305

Least Squares Means
Level
NS,C
NS,E
SM,C
SM,E

Least Sq Mean
4376.772
2253502.695
7613.300
1639204.088
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Std Error
615630.0431
502659.8253
767825.5661
638869.4883

Appendix: G.4
The expression of CYP3A7- Model with out interaction:
Response: 3A7
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.116652
0.083935
3435458
1357512
57

Effect Test
Source
SM/NS
REGION

Nparm
1
1

DF
1
1

Sum of Squares
3.60521e13
4.88614e13

F Ratio
3.0546
4.1400

Prob>F
0.0862
0.0468

Mean Square
4.208e13
1.18e+13

F Ratio
3.5655
Prob>F
0.0351

Whole-Model Test
Analysis of Variance
Source
Model
Error
C Total

DF
2
54
56

Sum of Squares
8.41631e13
6.37328e14
7.21491e14

SM/NS
Effect Test
Sum of Squares
3.60521e13

F Ratio
3.0546

DF
1

Prob>F
0.0862

Least Squares Means
Level
NS
SM

Least Sq Mean
544851.761
2178561.959

Std Error
588059.6219
737280.0049

Mean
733579
2350132

REGION
Effect Test
Sum of Squares
4.88614e13

F Ratio
4.1400

DF
1

Prob>F
0.0468

Least Squares Means
Level
C
E

Least Sq Mean
418070.379
2305343.342
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Std Error
723512.1544
599351.3975

Mean
240493
2113142

Appendix: G.5
The expression of CYP3A7- Model with interaction:
Response: 3A7
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.157827
0.110157
3385933
1357512
57

Effect Test
Source
SM/NS
REGION
SM/NS*REGION

Nparm
1
1
1

DF
1
1
1

Sum of Squares
2.36864e13
6.45753e13
2.97075e13

F Ratio
2.0661
5.6326
2.5913

Prob>F
0.1565
0.0213
0.1134

Whole-Model Test
Analysis of Variance
Source
Model
Error
C Total

DF
3
53
56

Sum of Squares
1.13871e14
6.07621e14
7.21491e14

Mean Square
3.796e13
1.146e13

F Ratio
3.3108
Prob>F
0.0269

SM/NS
Effect Test
Sum of Squares
2.36864e13

F Ratio
2.0661

DF
1

Prob>F
0.1565

Least Squares Means
Level
NS
SM

Least Sq Mean
661943.652
2010430.014

Std Error
584128.8916
734119.4659

Mean
733579
2350132

REGION
Effect Test
Sum of Squares
6.45753e13

F Ratio
5.6326

DF
1

Prob>F
0.0213

Least Squares Means
Level
C
E

Least Sq Mean
222917.228
2449456.437
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Std Error
723314.1745
597456.7408

Mean
240493
2113142

SM/NS*REGION
Profile Plot

LSMeans

20000000
15000000
10000000

3A7

5000000

SM
NS

0
C

E
REGION

Effect Test
Sum of Squares
2.97075e13

F Ratio
2.5913

DF
1

Prob>F
0.1134

Least Squares Means
Level
NS,C
NS,E
SM,C
SM,E

Least Sq Mean
303766.621
1020120.682
142067.836
3878792.193

138

Std Error
904928.588
738871.098
1128644.245
939088.776

Appendix: G.6
The differential expression of CYP3A3/A4 from Endo to Cervix
among nonsmokers:
3A3/A4 (Endo - Cerv)
Quantiles
maximum

quartile
median
quartile

minimum

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%

8473469
8473469
8473469
7552553
4252467
95130.8
34157.6
6189.92
3648.6
3648.6
3648.6

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

2046645
3018268
779313
3718102
375188
15
15

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t

0
2046645
t Test
2.6262
0.0199
0.0100
0.9900

3A7 (Endo - Cerv)
Quantiles
maximum

quartile
median

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
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1507322
1507322
1507322
1235049
995890
256011

quartile

minimum

25.0%
10.0%
2.5%
0.5%
0.0%

14651
-599496
-841414
-841414
-841414

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

335116.2
615457.1
158910.3
675944.2
-5711.8
15.0
15.0

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t
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0
335116
t Test
2.1088
0.0535
0.0267
0.9733

Appendix: G.7
The differential expression of CYP3A3/A4 from Endo to Cervix
among smokers:
3A3/A4 (Endo-Cervix)
Quantiles
maximum

quartile
median
quartile

minimum

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%

7757213
7757213
7757213
7757213
2263824
192003
10207.7
5232.99
5232.99
5232.99
5232.99

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

1431835
3103198
1266875
4688394
-1824724
6
6

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t

0
1431835
t Test
1.1302
0.3097
0.1548
0.8452

3A7 (Endo - Cervix)
Quantiles
maximum

quartile
median

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
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5398245
5398245
5398245
5398245
2009518
124588

quartile

minimum

25.0%
10.0%
2.5%
0.5%
0.0%

-126927
-581635
-581635
-581635
-581635

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

995062
2206636
900856
3310751
-1320627
6
6

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t

142

0
995062
t Test
1.1046
0.3196
0.1598
0.8402

Appendix: G.8
The differential expression from CYP3A3/A4 to CYP3A7 among
nonsmokers:
Endo (3A3-3A7)
Quantiles
maximum

quartile
median
quartile

minimum

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%

8358919
8358919
8358919
6693551
3366851
0
-392858
-1.33e6
-7.54e6
-7.54e6
-7.54e6

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

1162251
3439126
733224
2687062
-362560
22
22

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t

0
1162251
t Test
1.5851
0.1279
0.0639
0.9361

Cervix (3A3-3A7)
Quantiles
maximum

quartile
median
quartile

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%

143

19917.9
19917.9
19917.9
8014.84
0
-9100.2
-515000

minimum

10.0%
2.5%
0.5%
0.0%

-998318
-1.11e6
-1.11e6
-1.11e6

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

-213823.8
381793.3
98578.6
-2394.2
-425253.4
15.0
15.0

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t
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0
-213824
t Test
-2.1691
0.0478
0.9761
0.0239

Appendix: G.9

The differential expression from CYP3A3/A4 to CYP3A7 among
smokers:
Endo (3A3-3A7)
Quantiles
maximum

quartile
median
quartile

minimum

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%
2.5%
0.5%
0.0%

2312511
2312511
2312511
1702162
135476
-2.72e4
-3.81e6
-1.3e+7
-1.33e7
-1.33e7
-1.33e7

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

-2398596
5107828
1474503
846776
-5643967
12
12

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t

0
-2.4e+6
t Test
-1.6267
0.1321
0.9340
0.0660

Cervix (3A3-3A7)
Quantiles
maximum

quartile
median
quartile

100.0%
99.5%
97.5%
90.0%
75.0%
50.0%
25.0%
10.0%

145

0
0
0
0
-3958
-25908
-181024
-584723

minimum

2.5%
0.5%
0.0%

-584723
-584723
-584723

Moments
Mean
Std Dev
Std Error Mean
Upper 95% Mean
Lower 95% Mean
N
Sum Weights

-114712.2
230930.2
94276.9
127630.7
-357055.1
6.0
6.0

Test Mean=value
Hypothesized Value
Actual Estimate

Test Statistic
Prob > |t|
Prob > t
Prob < t
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0
-114712
t Test
-1.2168
0.2780
0.8610
0.1390
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